

## CURRICULUM VITAE

- 1. Name:** JUDITH ANN JOHNSON, PH.D.
  
- 2. Office Address:** University of Florida  
PO Box 100275  
Room M34  
Gainesville, FL 32610-0275  
**Telephone:** (352) 392-2165  
**Fax:** (352) 392-3053
  
- 3. E-Mail Address:** jajohnson@pathology.ufl.edu
  
- 4. Birth Date and Place:** May 19, 1956; Washington, DC
  
- 5. Citizenship:** United States of America
  
- 6. Current Titles and Affiliations:**  
  
2007 - present                    Professor  
Department of Pathology, Immunology, and  
Laboratory Medicine  
  
College of Medicine, and  
Institute,                            Director, Core Laboratories; Emerging Pathogens  
  
University of Florida; Gainesville, FL, USA
  
- 7. Previous Academic and Professional Appointments:**  
  
1999 - 2007                        Associate Professor  
Department of Pathology,  
Baltimore, MD                      University of Maryland School of Medicine,  
  
1998 - 2007                        Chief,  
Microbiology and Molecular Diagnostics,  
Veterans Affairs Maryland        Health Care System Baltimore, MD  
  
1999 - 2007                        Regular Member,  
Graduate Faculty, University of Maryland  
Graduate School,                    Baltimore, MD  
  
1998 - 2001                        Special Member,  
Graduate Faculty, University of Maryland  
Graduate School,                    College Park, MD  
  
2000 - 2007                        Associate Professor, secondary appointment,  
Department of Epidemiology and Preventive  
Medicine,

Baltimore, MD University of Maryland School of Medicine,

1993 - 2000 Assistant Professor, secondary appointment,  
Department of Medicine,  
University of Maryland School of Medicine,  
Baltimore, Maryland.

1999 - 2000 Associate Professor, secondary appointment,  
Department of Medicine, Division of Hospital  
Epidemiology,  
Baltimore, Maryland. University of Maryland School of Medicine,

1994 - 1999 Associate Member,  
Graduate Faculty,  
Baltimore, Maryland. University of Maryland Graduate School,

1993 - 1999 Assistant Professor  
Department of Pathology, University of Maryland  
School of Medicine,  
Baltimore, Maryland.

1993 - 1998 Scientific Director,  
Molecular Diagnostic Laboratory, Veterans  
Affairs Maryland Health  
Care System Baltimore, Maryland.

1982-1990 Graduate Teaching Assistant,  
Department of Microbiology, University of  
Maryland, College Park

1977-1982 Medical Technologist, Microbiology  
Section,  
Prince George's General Hospital & Medical  
Center, Cheverly, MD

## 8. Education

1977 B.S., University of Maryland at College Park  
(Microbiology)

1990 Ph.D, University of Maryland at College Park  
(Microbiology)

## 9. Postdoctoral Training:

1990-1993: Center for Vaccine Development, University of  
Maryland School of  
Medicine

## 10. Certifications

1978 - present M(ASCP)

1978 - present RM (AAM)

**11. Committee Memberships**

**a. National and International**

1975 - present  
1983 Member of the American Society for Microbiology  
Member of the American Academy of Microbiology,  
National Registry of Microbiologists  
Examination Development Committee  
Member of the American Association for the

1986 - 2003  
Advancement of Science Member of the American Association of University

1995 - 2005  
Women External Reviewer, USDA - Insuring Food Safety

1996 - 2002  
grant program Reviewer Virulence Factor Activity

2004  
Relationships (VFAR) with Specific Emphasis on *Aeromonas* species

(spp.). Ashok K. Chopra, EPA Workshop on Virulence Factor-

Activity Relationships External Reviewer, Grant for Wisconsin Water

2005 Resources Institute (WRI)

2005 External Reviewer, NSF OISE- International

Fellows Program

**b. Local**

1988 Graduate Student Member, Faculty Search

Committee, Department of Microbiology, UMCP

1993 External Reviewer, Maryland Sea Grant

Preproposals Member, Veterans Affairs Maryland Health Care

1993 - 1998 System Baltimore, Research and Development Committee

1993 - 2007 System Member, Veterans Affairs Maryland Health Care

Service, Total Baltimore, Pathology and Laboratory Medicine

1994 Quality Improvement Committee

System Member, Veterans Affairs Maryland Health Care

1994 - 2007 Baltimore, Research Budget Committee

Branch American Society for Microbiology, Maryland

1995 - 1998 System Member, Veterans Affairs Maryland Health Care

1995, 1996 Baltimore, Research Resources Committee

1996, 1997, 1999 American Society for Microbiology, Maryland

1997-1998 Society Judge, Student Science Fair

Judge - UMAB/UMBC Graduate Student Research Day

Alternate Councilor, Maryland Branch, American

	for Microbiology Baltimore, Research Seminar Committee Councilor, Maryland Branch, American Society
1998- 1999 for Microbiology System	Member, Veterans Affairs Maryland Health Care Baltimore, Dream Team
1998 - 1999 System	Member, Veterans Affairs Maryland Health Care Baltimore, Core Equipment Committee
1998 Department ,	Member, Productivity Committee, Pathology University of Maryland, Baltimore
1999 - 2007 UMB	Member, Pathology Department Mentoring Program Member, Veterans Affairs Maryland Health Care
1999 - 2005 System	Baltimore, Infection Control Subcommittee Member, Veterans Affairs Maryland Health Care
1999 - 2005 System	Executive Infection Control Committee Pathology Department Planning Program Leader - Infectious Diseases, University of Maryland,
1999- 2000 Baltimore System	Member, Veterans Affairs Maryland Health Care Baltimore, Animal Use Committee
1999- 2000 Society for Microbiology	Vice President, Maryland Branch, American
2000- 2001 Society for Microbiology	President Elect, Maryland Branch, American
2000 - 2001 Medicine	Alternate, University of Maryland School of Council, University of Maryland, Baltimore
2000 - 2005 Committee,	Pathology Department Graduate Admissions University of Maryland, Baltimore
2001- 2005 Research and	Assistant Secretary/Treasurer - Baltimore Education Foundation
2001 - 2002 for Microbiology	President, Maryland Branch, American Society
2002 - 2003 Society for Microbiology	Past President, Maryland Branch, American
2001 - 2007 System	Member, Veterans Affairs Maryland Health Care Baltimore, Human Studies Subcommittee
2003 2005 - 2007 System	CAP inspection team for St. Mary's Hospital Member, Veterans Affairs Maryland Health Care Acute Care Infection Control Subcommittee
2005 - 2007 Baltimore	Member, Pathology Research Advisory Committee, Pathology Department, University of Maryland, CAP inspection team for Mercy Hospital
2005	

2005 - 2007  
Education Foundation  
2006  
2006  
Analysis)  
Health Care System  
2006 - 2007  
Maryland  
2006 - 2007  
Zero, Laboratory  
Health Care System  
2008  
Department of  
2008  
2008  
Emerging Pathogens

Secretary/Treasurer - Baltimore Research and  
CAP inspection team for St. Agnes Hospital  
HFMEA (Healthcare Failure Mode and Effect  
Team for Isolation, Veterans Affairs Maryland  
Pandemic Influenza Work Group, Veterans Affairs  
Health  
Care System  
VHAPTH MRSA Prevention Initiative - Getting to  
Representative, Veterans Affairs Maryland  
Mentoring Committee for Dr. Bin Gao, IFAS,  
Agricultural and Biological Engineering  
Member Search Committee for faculty candidate,  
Emerging  
Pathogens Institute  
Chair Search Committee for faculty candidate,  
Institute

**12. Manuscript Reviewer:**

*Vibrio cholerae* and Cholera: Molecular to Global Perspectives.

1994. ASM Washington DC	1993	
Clinical Infectious Diseases	1996 - 2005	
Infection and Immunity	1997 - 2004	
Clinical and Diagnostic Laboratory Immunology		1998
Journal of Clinical Microbiology	2003 - present	
Emerging Infectious Diseases	2004 - present	
Clinical Microbiology Reviews	2006	
Antimicrobial Agents and Chemotherapy	2006	
Applied and Environmental Microbiology	2006 - present	

**13. Honors and Awards:**

1984  
Graduate Student,  
Maryland  
1988  
Graduate Student,  
Maryland  
1994  
Rewards (STAR) Award,  
Risk Reduction

Isabel R. MacDonald Award to an Outstanding  
Department of Microbiology, University of  
Andrew J. Myer Award to an Outstanding  
Department of Microbiology, University of  
Scientific and Technological Achievement  
United States Environmental Protection Agency,  
Engineering Laboratory

**14. Research Focus:**

**Microbial pathogenesis** - Ongoing projects: the role of surface polysaccharides in pathogenesis, immunity, and evolution of *Vibrio* spp.; causes of neonatal sepsis in India; causes of diarrheal disease in Maryland; and distribution and horizontal transfer of virulence genes in vibrios and other pathogens.

**Antibiotic resistance** - Ongoing projects include molecular mechanisms, development of models for transmission of vancomycin, quinupristin/dalfopristin, and high level aminoglycoside resistant enterococci and extended spectrum beta lactamase resistance in Gram negative bacteria. Role of agricultural use of antibiotics in clinical resistance.

**Microbial physiology** - Ongoing projects: genetic regulation of vibrio polysaccharides, mutator genes in expression of the rugose survival form of *V. cholerae*.

**Molecular epidemiology** - Ongoing projects: epidemiology of nosocomial infections; use of PCR and probes to follow transmission of vancomycin and high level aminoglycoside resistance genes; and molecular typing of enterococci, *V. cholerae*, pneumococci, methicillin resistant *Staphylococcus aureus* (MRSA) and other organisms.

**Microbial ecology** - Ongoing projects: characterization of populations by Multilocus sequence typing (MLST) sequencing. Environmental impacts of agricultural use of antibiotics.

**15. Patents:**

5653986 Morris, J. G., Jr., Johnson, J. A., and Bush, C. A. "*Vibrio cholerae* Bengal serogroup-O139 capsular polysaccharide, protein conjugates thereof" (U. S. Patent, awarded 8/5/97)  
60/761,225 Panigrahi P, Johnson J, Gewolb IH, Parida SN, Msra PR, Mhapatra SS, Pradhan L, Satpathy R "Fructo-oligosaccharide and Lactobacillus Combination and Uses Thereof" (pending)

**16. Grant Support:**

**a. Active Grant Support**  
**Principle Investigator**

**Other**

**b. Pending Grants**  
**Principle Investigator**

**Other**

**Title:** Effect of Bacterial Motility on E. coli Surface Runoff Transport through Dense Vegetation

**Source:** USDA

**Mechanism of Support:** CSREES

**Role on Project:** Co-PI

**Total Cost:** \$398,637

**Dates:** 10/01/2008 - 9/30/2011

**c. Previous Support  
Principle Investigator**

1/1/94 - 12/30/95  
Rugose *Vibrio*

Affairs RAGS

4/1/96 - 3/31/99  
*Vibrio cholerae*.

Review

5/1/94 - 4/30/99  
Bengal

\$440,661

3/1/98 - 2/28/00  
*Enterococci* in Poultry

(deceased)

6/1/99 - 12/31/00  
Against Gram

6/1/03 - 6/30/04  
Microbiology

6/1/02 - 12/31/02  
Collection Methods

10/1/01 - 9/30/04  
Review

**Other**  
7/1/93 - 6/30/95  
*cholerae*

Jr., M.D.

Colonization and Biofilm Formation -  
*cholerae* Model. Department of Veterans

Total direct costs: \$100,000  
Genetics of the Rugose Survival Form of  
Department of Veterans Affairs Merit

Total direct costs: \$212,000  
Current year direct costs: \$65,800  
Continuation of VA RAGS project  
Pathogenesis of *Vibrio cholerae* O139 Synom

NIH-R29, AI35729  
Total direct costs: \$350,000, total costs:

Current year direct costs: \$69,408  
Quinupristin/Dalfopristin Resistant

Pfizer Inc.  
Total direct costs: \$105,780  
Principal Investigator: Richard Schwalbe

Change of P.I. to Judith A. Johnson 11/98  
Activity of Tetracycline Derivatives

Positive Bacteria  
Paratek, Inc.  
Total direct costs \$67,076  
Evaluation of the PHOENIX™ Automated

System  
BD Biosciences  
Total direct costs: \$63,900

Clinical Impact of Blood Culture

BD Biosciences  
Total direct costs: \$48,000  
Antibiotics and Resistant Enterococci.  
Department of Veterans Affairs Merit

Total direct costs: \$550,000  
First year direct costs: \$185,200

Impact of Rugose Survival Form of *Vibrio*

on Transmission of Cholera.  
Thrasher Research Foundation  
Principal Investigator: J. Glenn Morris,

effort

8/1/95 - 7/30/96  
of Common

Phase II

5% effort

\$105,000

9/1/96 - 8/31/97  
Methods for the

the *Bdellovibrios*.

effort

11/1/97 - 10/31/98  
water temperature and

occurrence of cholera

Jr., M.D.

Johnson, 5% effort,

\$69,961

9/1/96 - 12/31/98  
Program in

Prevention

H. Harrison, J.

5% effort

costs: \$1,835,841

\$72,201)

1/1/98 - 9/30/98

10/1/98 - 9/30/99

Jr., M.D.

Co-principal: Judith A. Johnson, Ph. D. 5%

Total direct costs: \$85,354

Molecular Epidemiology and Identification

Surface Antigens in Enterococci, MPS,

Principal Investigator: Richard Schwalbe

Co-investigator: Judith A. Johnson, Ph. D.

Total direct costs \$84,000, total costs:

Preliminary Exploration of Molecular

Specific Detection and Differentiation of

National Science Foundation

Principal Investigator: Henry N. Williams

Co-investigator: Judith A. Johnson 5%

Total direct costs \$51,720, total \$74,994

Assessment of the predictive value of

other environmental parameters on

Thrasher Research Foundation

Principal Investigator: J. Glenn Morris,

Co-Principal Investigator: Judith A.

Total Direct costs, \$66940, Total Costs

A Proposal for an Emerging Infections

Maryland, Centers for Disease Control and

Principal Investigators: Diane Dwyer, Lee

Glenn Morris, Jr.

Co-investigator: Judith A. Johnson, Ph. D.

Total direct costs \$1,497,846, total

First year direct costs: \$475,850 (UMAB

NSF OCE-97310055

Assesment of Diversity Among *Bdellovibrios*

Total direct costs: \$60,000

Principal Investigator: Henry N. Williams

Consultant: Judith A. Johnson 5%

Dose-response to *Vibrio* species

FDA

Principal Investigator: J. Glenn Morris,



effort,

\$941,967

10/1/97 - 9/30/00  
horizontal gene

Affairs, VA/DOD

Jr.

2/1/00 - 1/31/01  
Quinupristin/Dalfopristin

Jr.

7/1/99 - 6/30/03  
Island

costs: \$1,537,553

effort

6/1/00 - 5/31/01  
Microbiology

9/1/00 - 8/31/01  
surface water

Silbergeld

9/1/00 - 8/31/01  
Food Animals,

10/1/01-12/31/02  
Understanding their

Co-Investigator: Judith A. Johnson, 5%

Total Direct costs, \$721,637; Total Costs

Emergence of new pathogens: Role of

transfer in *Vibrio*. Department of Veterans

Principal investigator: J. Glenn Morris,

Co-investigator: Judith Johnson 5% effort

Total direct costs: \$300,000

Current year direct costs \$99,956

Risk Assessment of Use of

in Animals/Animal Feed

Pfizer Inc.

Total direct costs: \$135,000

Principal Investigator: J. Glenn Morris,

Co-investigator: Judith Johnson 10% effort

Analysis of the *Vibrio cholerae* Pathogenicity

NIH ROI

Total direct costs: \$1,039,798, Total

First year direct costs: \$196,982

Principal Investigator: David Karaolis

Co-investigator: Judith A. Johnson, 5%

Evaluation of the PHOENIX™ Automated

System

BD Biosciences

Principal Investigator: Patrick R. Murray

Co-principal Investigator: Judith Johnson

Total direct costs: \$67,300

An evaluation of the groundwater and

impacts of swine CAFOs in Maryland

Principal Investigator: Ellen K.

Co-investigator: Judith Johnson 10% effort  
CDC

Total direct costs: \$207,229

Survey of Antibiotic Resistant Bacteria in

Poultry Workers, and Human Referent Groups  
PHS/FDA/CVM

Principal Investigator: O. Colin Stine

Co-director: Judith Johnson 5% effort

Total Direct costs, \$114,000

First year direct costs: \$114,000

Ureidopenicillins and Carbapenems:

antibiotic-resistance

9/1/01 - 8/31/06

Health Research

4/01/03 - 3/31/06

Resistance After

Review

Roghmann.

10/01/04 - 9/30/07

Pathogen Detection

Illness

effort

4/1/05 - 3/30/09

*Pseudomonas aeruginosa*

4/1/06 - 3/30/09

Carriage at Hospital

Perencovich.

1998 - 1999

ESBL producing

cefepime,

relative importance as risk factors for

Merck & Co., Inc.

Principal Investigator: Anthony Harris, MD

Co-investigator: Judith Johnson 5% effort

Total direct costs: \$30,000

First year direct costs: \$30,000

Prevention of Infection in Indian Neonates  
NIH

Global Network for Women's and Children's

Principal Investigator: Pinaki Pani grahi

Co-director: Judith Johnson 10% effort

Total direct costs: \$3,233,856

First year direct costs: \$499,079

Molecular Epidemiology of Antibiotic

Spinal Cord Injury

Department of Veterans Affairs Merit

Principal Investigator: Mary-Claire

Co-investigator: Judith Johnson 10% effort

Total direct costs: \$418,900

First year direct costs: \$139,400

Diarrhea in Baltimore: Surveillance and

Discovering Novel Causes of Foodborne

Principal Investigator: Jon Mark Hirshon

Co-investigator: Judith A. Johnson 5%

Total direct costs \$707,067

First year direct costs: \$235,689

Epidemiology of Imipenem-resistant

NIH R01 AI060859

Principal Investigator: Anthony Harris.

Co-investigator: Judith Johnson 5% effort

Total direct costs: \$850,000

First year direct costs: \$250,000

Predicting Antibiotic Resistant Bacterial

Admission

Department of Veterans Affairs HSR&D

Principal Investigator: Eli N.

Co-investigator: Judith Johnson 10% effort

Total direct costs: \$704,200

First year direct costs: \$244,800

**Contracts and Small Grants, PI**

Clinical outcome of infections caused by

strains of *Klebsiella* and *E. coli* treated with

subcontract for microbiology  
1999  
multiresistance in  
1998

(completed)  
1999  
susceptible *E. faecalis*  
ciprofloxacin, levofloxacin

(completed)  
1999  
vitro Susceptibility of  
costs \$5,000

2000  
multiresistance in  
1999

(completed)  
2000

(completed)  
10/99 - 6/00  
Surveillance Study for  
099E)

Management

(completed)  
8/3/99

1999  
*aeruginosa*

(completed)  
2000  
Study)

2000  
susceptible *E. faecalis*  
ciprofloxacin, levofloxacin

in clinically ill surgical patients,  
ICU Surveillance Study (ISS): Incidence of  
serial Gram-negative isolates from ICUs -

Merck & Co., Inc. Total costs - \$1,500

In vitro evaluation of vancomycin  
against imipenem, meropenem

and trovofloxacin - 1998

Merck & Co., Inc. Total costs - \$750

Moxifloxacin Regional and National In-

Common Respiratory Tract Pathogens (MSP)  
Bayer, Co/The SuperNova Co. Total

(completed)

ICU Surveillance Study (ISS): Incidence of  
serial Gram-negative isolates from ICUs -

Merck & Co., Inc. Total costs - \$1,500

Newer Beta-Lactamases Project  
Merck & Co., Inc. Total costs - \$1590

Comparative In Vitro Microbiologic

Respiratory Tract Infection (1273-BMS-

Bristol-Myers Squibb/International Health

Associates, Inc. Total costs \$5,000

Molecular typing of enterococcal isolates  
Pharmacia & Upjohn Total costs \$500

Analysis of Imipenem Resistant *Pseudomonas*

Isolates

Merck & Co., Inc. Total costs - \$3,500

The ZAPS (Zyvox® Antimicrobial Potency

The Clinical Pharmacokinetics Laboratory  
Total costs \$2150 (completed)

In vitro evaluation of vancomycin

against imipenem, meropenem

and moxifloxacin - 1999 Merck & Co., Inc.  
Total costs - \$1500 (completed)

2001  
multiresistance in

2001

(completed)

2001  
Gatifloxacin,

Gemifloxacin against

2001  
Reproducibility of the

Detection of Urinary

Osmetech plc

2001  
microbiology

2002  
multiresistance in

2002

(completed)

**Clinical trials supported by VAMHCS Clinical Microbiology and Molecular Diagnostics Laboratory**  
1998 - 1999

Resistant

Trial Comparing

mg Linezolid

1998-1999  
Safety and Effectiveness

Anti-*Clostridium*

(DiffGAM<sup>™</sup>)

Associated Diarrhea

1999  
Randomized,

Tolerability, and

Sodium in the

ICU Surveillance Study (ISS): Incidence of  
serial Gram-negative isolates from ICUs -

Merck & Co., Inc. Total costs - \$1,500

In Vitro Comparison of the Activity of

Levofloxacin, Grepafloxacin, and

Clinically Important Organisms.

SmithKline Beecham Pharmaceuticals

Total costs - \$5000 (completed)

Evaluation of Intra-Site Performance

Osmetech Microbial Analyser<sup>™</sup> in the

Tract Infection. Protocol #CP-004-C

(completed)

PROTEKT-US Respiratory Survey. clinical

Institute (completed)

ICU Surveillance Study (ISS): Incidence of

serial Gram-negative isolates from ICUs -

Merck & Co., Inc. Total costs - \$1,500

Linezolid for the Treatment of Vancomycin-

Enterococcal Infections: A Double-Blind

600 mg Linezolid Every 12 Hours with 200

Every 12 Hours M1260/0054

Pharmacia & Upjohn

Phase II Clinical Trial to Evaluate the

of an Enterocolonic Formulation of Bovine

*difficile* Toxin A and B Milk Immunoglobulin

on Reducing the Severity of *C. difficile*

(CDAD)

ImmuCell Corporation #ICC-0302-1988

A Prospective, Multicenter, Double-Blind,

Comparative Study to Evaluate the Safety,

Efficacy of MK-0826 Versus Ceftriaxone

Pneumonia

1999  
Double-Blind, Placebo-

Ramoplanin and

Gastrointestinal System

Enterococcus.

1999  
Randomized,  
Tolerability, and

Sodium in the

Infections

1999  
Randomized,

Tolerability, and

Piperacillin/Tazobactam in the

Structure Infections

1999 - 2000  
Multicenter Phase III

7.5 mg/kg q 8

Standard Therapy

Hospitalized Patients

part, to Gram

Development

2000  
Randomized Study to

Daptomycin with that

Penicillin in the Treatment

Tissue Infections Due

Treatment of Serious Community-Acquired

in Adults. Merck & Co. Inc.  
A Phase-II, Randomized, Multicenter,

Controlled Study to Compare Two Doses of

Placebo in the Decontamination of the

Colonized by Vancomycin-Resistant

Pharmaceutical Research Associates, Inc.  
A Prospective, Multicenter, Double-Blind,

Comparative Study to Evaluate the Safety,

Efficacy of MK-0826 Versus Ceftriaxone

Treatment of Complicated Urinary Tract

in Adults.

Merck & Co. Inc. #014-00  
A Prospective, Multicenter, Double-Blind,

Comparative Study to Evaluate the Safety,

Efficacy of MK-0826 Versus

Treatment of Complicated Skin and Skin

in Adults.

Merck & Co. Inc. #016-00  
Open-Label, Comparative, Randomized,

Study of Intravenous Treatment of Synercid

hours plus Aztreonam 2g q 8 hours versus

in the Treatment of 250 Adult Evaluable

with Nosocomial Pneumonia due, at least in

Positive Cocci.

Rhone-Poulenc Rorer Recherche-

RP59500V-311

A Multicenter, Investigator-blinded,

Compare the Safety and Efficacy of IV

of Vancomycin or a Semi-Synthetic

of Complicated Bacterial Skin and Soft

to Gram-Positive Bacteria

#018-00

SST9801

2002 - 2003  
the Efficacy

Intravenously in the  
Diabetic Inpatients

#0910X-100468-US  
2002 - 2003  
Double-Blind with

Study to

Tolerability, of Ertapenem  
the Treatment of  
Hospitalized

2002 - 2003  
Multicenter, Double-Blind

Comparative Study to

Tolerability, of Ertapenem  
the Treatment of

ERT502/ Protocol 034  
2003 - 2004  
Phase III,

and Zyvox

Hospitalized Adults with  
Enterococcal Infections

VRE-00-07

2003 - 2004  
Comparative Study of

Preemptive

Intensive Care Unit

Micafungin

2003 - 2004  
multicenter study to

Cubist Pharmaceuticals, Inc. DAP-

An Open-Label, Randomized, Study Comparing  
and Safety of Piperacillin/Tazobactam and  
Ampicillin/Sulbactam Administered

Empirical Treatment of Foot Infections in  
Wyeth-Ayerst Pharmaceuticals Inc.

Stitch Study. A Prospective, Multicenter,  
In-House Blinding, Randomized, Comparative  
Evaluate the Efficacy, Safety, and

Sodium Versus Piperacillin/Tazobactam in  
Complicated Intra-Abdominal Infections in  
Adults.

Merck & Co. Inc. #037-01 - ERT516  
Side Step Study. A Prospective,

with In-House Blinding, Randomized,  
Evaluate the Efficacy, Safety, and

Sodium Versus Piperacillin/Tazobactam in  
Diabetic Foot Infections in Adults.

Merck & Co. Inc. #034 -

A Randomized Double-Blind, Double-Dummy,  
Comparative Study of Cidecin (Daptomycin)  
(Linezolid) in the Treatment of

Suspected Vancomycin-Resistant

Cubist Pharmaceuticals, Inc. DAP-

A Phase III, Randomized Double-Blind,  
Micafungin (MK463) Versus placebo as  
Antifungal Therapy in Patients in the

Fujisawa healthcare Inc #01-0-124

Phase III, Randomized, double-blind,

dalbavancin versus  
uncomplicated skin and soft  
confirmed gram positive

2003 - 2004  
multicenter study to

dalbavancin versus  
uncomplicated skin and soft  
confirmed gram positive

2003 - 2004  
Blinding, Randomized,  
Efficacy, Safety, and  
Piperacillin/Tazobactam in  
Abdominal Infections

2004  
Blind,  
Safety of  
the Treatment of

2004 - 2007  
Blind,  
Safety of  
Subjects  
Pneumonia.

2004 - 2007  
Multicenter  
of  
Treatment of  
Infections with Suspected  
Pathogens.

evaluate the safety and efficacy of  
cefazolin in the treatment of  
tissue infections with suspected or  
bacterial pathogens

Versicor, Inc. VER001-8  
Phase III, Randomized, double-blind,

evaluate the safety and efficacy of  
linezolid in the treatment of  
tissue infections with suspected or  
bacterial pathogens

Versicor, Inc. VER001-9  
A Prospective, Multicenter, Double-

Comparative Study to Evaluate the  
Tolerability, of Ertapenem Versus  
the Treatment of Complicated Intra-

in Hospitalized Adults. (Stitch Study)  
Merck & Co. Inc. ERT516 #037-011

A Phase3, Multicenter, Randomized, Double-  
Comparative Study of the Efficacy and  
Tigecycline versus Imipenem/Cilastatin for

Subjects with Nosocomial Pneumonia.  
Wyeth, Inc. 3074A1-311-WW

A Phase3, Multicenter, Randomized, Double-  
Comparative Study of the Efficacy and  
Tigecycline versus Levofloxacin to Treat  
Hospitalized with Community-Acquired

Wyeth, Inc. 3074A1-308-WW  
A Phase III, , Randomized, Double-Blind,

Study to Evaluate the Safety and Efficacy

Dalbavancin versus Cefazolin in the  
Uncomplicated Skin and Soft Tissue  
or Confirmed Gram-Positive Bacterial

2004 - 2007  
Multicenter  
of  
Treatment of  
Infections with Suspected  
Pathogens.

Versicolor, Inc. VER001-8  
A Phase III, , Randomized, Double-Blind,  
Study to Evaluate the Safety and Efficacy  
of Dalbavancin versus Linezolid in the  
Treatment of Complicated Skin and Soft Tissue  
Infections or Confirmed Gram-Positive Bacterial

2004 - 2007  
Vancomycin/Oxacillin/Dicloxacillin in the  
Treatment of Positive Bloodstream

Versicolor, Inc. VER001-9  
Linezolid vs.  
Treatment of Catheter-Related Gram-  
Positive Bloodstream  
Infections

2005 - 2006  
Compare the  
Efficacy of Doripenem with that of  
Meropenem in Hospital

Pharmacia PHA- OXAA- 0026  
A Multicenter, Open-Label Phase 3 Study to  
Evaluate the Safety and Efficacy of Intravenous  
Doripenem versus Intravenous Imipenem in Ventilator-

10  
2005 - 2006  
Compare the  
Efficacy of Doripenem in Hospital

Peninsula Pharmaceuticals, Inc. DORI -  
A Multicenter, Open-Label Phase 3 Study to  
Evaluate the Safety and Efficacy of Intravenous  
Doripenem versus Intravenous Imipenem in Hospital

2005 - 2006  
Patients in the

Acquired Pneumonia  
Peninsula Pharmaceuticals, Inc. DORI -9  
Mecafungin (FK463) versus Placebo in  
Hospitalized Patients in the  
Intensive Care Unit

124  
2005 - 2007  
Subjects with  
Infections Proved to be Due

Fujisawa Pharmaceuticals, Inc. 01-0-  
LEAPS: Linezolid in the Treatment of  
Complicated Skin and Soft Tissue  
Infections due to Methicillin-Resistant *Staphylococcus aureus*.

2006-2007  
Trial of Rifamixin  
of *Clostridium*

Pfizer, Inc. A5951002  
A Double-Blind, Randomized, Controlled  
Study Comparing the Efficacy and Safety of  
Rifamycin B (Rifampin) versus Vancomycin for the Treatment  
of Clostridium difficile-Associated Diarrhea (CDAD).  
Salix Pharmaceuticals, Inc..

Xifaxan RFCL3001  
2006  
2006  
2006-2007  
2006-2007

Theravance, Inc. 0015  
Theravance, Inc. 0018  
Genzyme Co. GD3- 170- 301  
A phase 3, multicenter, randomized,  
double-blind, comparative study to



- 2006-2007 evaluate the safety and efficacy of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin and skin structure infection.  
Cerexa P-903-06 and P-903-07.
- 2006 -2007 A phase 3, randomized, double-blind, study of Ceftobiprole medocartil vs linezolid plus ceftazidime in the treatment of nosocomial pneumonia.  
Advanced Biologics  
BAP00248.
- 2006 -2007 Study of the efficacy and safety of moxifloxacin in the treatment of diabetic subjects with infections of the foot  
Schering-Plough Research Institute  
P05000.

**17. Teaching Activities:**

Dissertation or Thesis Committees/ Examiner  
Graduates

- 1994  
*Streptococci*  
J. Glenn Morris, Jr.)  
1995  
J. Glenn Morris, Jr.)  
1997  
immunotherapy against  
advisor,  
1998  
Determination of the absolute  
capsular polysaccharides  
Allen Bush)  
1999  
Craniofacial  
Characterization of  
advisor  
1998  
characterization of the rugose  
supervision; primary  
1999  
animal model.  
1999  
Maryland,  
Investigation of  
polysaccharides by  
magnetic resonance  
Bush)
- Taheri S. Lashkerwala**, M.S. Project:  
Molecular Epidemiology of Group B  
(direct supervision; primary advisor Dr.  
**Augusto Franco**, Ph.D.  
Universidad Peruana Cayetano Heredia, Lima  
Project: Rugosity and *dnaE* in *Vibrio cholerae*  
(direct supervision; primary advisor Dr.  
**Thomas P. Iarrocci**, M.S., Project:  
Role of investigational antibiotics and  
multiply-resistant enterococci (primary  
Dr. Richard Schwalbe)  
**Tuhui Wang**, M.S. Department of Chemistry and  
Biochemistry, UMBC. Project:  
configuration of sugar residues in the  
of *Vibrio vulnificus*. (primary advisor Dr. C.  
**Marcie L. Baer**, Ph.D., Department of Oral and  
Biological Sciences. Project: Molecular  
the Bacterial Predator, *Bdellovibrio* (primary  
Dr. Henry Williams)  
**Mohammed Afsar Ali**, Ph.D., MEES Program  
Project: Phenotypic and genetic  
variant of *Vibrio cholerae* (direct  
advisor Dr. J. Glenn Morris, Jr.)  
**S. Srinivas**, Ph.D., Department of Pathology  
Project: Development of a transgenic  
(primary advisor Dr. Louis J. DeTolla)  
**Shamantha Gunawardena**, Ph.D., Department of  
Chemistry and Biochemistry, University of  
Baltimore Campus. Project: Structural  
pathogenic bacterial capsular  
heteronuclear multidimensional nuclear  
spectroscopy (primary advisor C. Allen

2000  
and  
Baltimore Campus.  
specific degradation of  
*cholerae* O139

**Xueling Lu**, M.S., Department of Chemistry  
Biochemistry, University of Maryland,  
Project: Preliminary investigation on  
the capsular polysaccharide of *Vibrio*  
(primary advisor C. Allen Bush)

2000  
*Bdellovibrio*

**Andrew Snyder**, Masters student MEES Program  
Project: Diversity and Ecology of

2001  
Cluster in *Vibrio cholerae*

(primary advisor, Henry Williams)  
**Cara Fiore**, Ph.D. - Toxicology Program  
Project: Role of wbfH, I, and J Gene

2001  
Pathology  
*Vibrio cholerae* O139

O139 Capsule Production  
**Ellen (Trigiani) Fernandez**, Ph.D., Department of

Cell Mediated

Project: The Capsular Polysaccharide of  
Bengal: Induction and Modulation of Host-  
Immune Responses

2001  
of Medical and  
Streptogramin Resistance in  
advisor)

**Sadaf Qayumi**, Masters Student - Department  
Research Technology Project:

2001  
Pathology  
High-Level  
from

*Enterococcus faecium* (direct supervision; co-

1995 - 2001

**Angela McIntosh**, Ph.D., Department of  
Project: Recovery and Characterization of  
Gentamicin Resistant Strains of *Enterococci*

Jr.)

1999-2003

Commercial Poultry  
**Amy Carnahan**, Ph.D. student, MEES Program  
Project: Molecular characterization  
(primary advisor, Dr. J. Glenn Morris,

dental units. Dean's

**Ruby Singh**, Ph.D. MEES Program  
Project: Characterization of biofilms in  
representative (primary advisor, Henry

Williams)

2002 - 2004

Human

**Antonina Aydanian**, Ph.D. student, Program in  
Genetics. (primary advisor Dr. O. Colin

Stine)

Project: Recombination in the Bacterium

*Vibrio cholerae*

2002 - 2004

Epidemiology

**John Furuno**, Ph.D. student, Department of

of *Aero*

representative (primary

Project: Predicting Antibiotic

Admission

2000 - 2005  
of Pathology

Project:

Hepatocytes

Direct Hepatic

Wilson's Disease

2005  
of Pathology

Project: Human

Investigations of a

2004 - 2006  
(primary

Project: *V. cholerae*

2004 - 2007  
University

2004 - present

Mycobacterial

Ongoing

Supervision of Other Graduate Students and Fellows

1994-1995

of capsule

(direct supervision;

of Medicine).

1996

Mark Steinhoff)

1996

Fellow.

labelled probes for

and Preventive Medicine. Deans

advisor Dr. Eli Perencevich).

Resistance Outcomes upon Hospital

**Rigoberto Sanchez**, Ph.D. student, Department

(primary advisor Dr. Louis J. DeTolla).

Transplantation of Genetically Modified

Containing a Copper-Transporting ATPase,

Delivery, and the Potential Treatment of

**Daniel C. Edelman**, Ph.D. student, Department

(primary advisor Dr. Louis J. DeTolla).

Herpes Virus 8: Diagnosis and Serologic

Novel Human Pathogen

**Yuansha Chen**, Ph.D. student, MEES Program

advisor Dr. J. Glenn Morris, Jr.)

**Mohammed H. Raschid**, Ph.D. student, Dhaka

(primary advisor Dr. Glenn Morris).

Project: Genetics and Physiology of the  
Rugose Phenotype of *Vibrio cholerae*.

**Cynthia Stine**, Graduate Student MEES

(primary advisor Dr. Andrew Kane) Project:

infections of fish

**Laurie Comstock-Villa**. Postdoctoral Fellow

Project: Characterization of the genetics

biosynthesis in *V. cholerae* O139 Bengal

primary advisor James B. Kaper, Department

**N.K. Brahmadathan**, Research Fellow, JHU

Project: Molecular typing of pneumococci.

(direct supervision; primary advisor, Dr.

**James Allen Krum**, Lockheed-Martin Graduate

Project: Development of nonradioactively-

*Enterococci.*

1998 - 1999  
Department of  
for vancomycin  
2001- 2002  
commensals of poultry  
2001- 2002  
UMCP  
capsule of *Vibrio*  
Bush. )  
2002 - 2003  
Department of  
(primary advisor  
intensive care setting  
2002 - 2003  
of  
(primary advisor Dr.  
resistant  
setting or Risk  
resistant pseudomonas  
2003 - 2004  
2004  
flora of spinal cord  
2004  
2005  
1996 - present  
of  
of multiresistant  
hospitalized

antimicrobial resistance genes in  
**Kerri-Lynn Sheahan**, Masters Student  
Pathology. Project: Bacteriophage therapy  
resistant enterococci  
**Damiola Akinmade**, Graduate Student, rotation  
Department of Pathology  
Project: Antibiotic resistance in  
**Jacob Adeyeye**, Postdoctoral Fellow,  
Department of Chemistry and Biochemistry,  
Project: Interaction of phage with the  
*cholerae* O139 (Codirection with Dr. C. Allen  
**Lucia Nemoy**, Infectious Diseases Fellow,  
Epidemiology and Preventive Medicine.  
Dr. Anthony Harris)  
Project: Carriage of ESBLs in the  
**Aileen Dualen**, ABD Ph.D. student, Department  
Epidemiology and Preventive Medicine.  
Anthony Harris). Project: Fluoroquinolone  
*Pseudomonas aeruginosa* in the intensive care  
Factors for the acquisition of imipenem-  
*aeruginosa* among ICU patients.  
**Habibul Bari Mahmud Bakht**, Ph.D. student,  
MEES Program Withdrew  
**Zachary Cooper** Ph.D. Student, rotation  
Department of Pathology  
Project: Antibiotic resistance in enteric  
injury patients.  
**Patricia Anderson**, Ph.D. student, rotation  
Department of Pathology  
Project: Mitator strains in *Vibrio cholerae*  
**Maureen O'Donnel** Ph.D. Student, rotation  
Department of Pathology  
Project: Antibiotic resistance  
**Scott A. Thornton**, Ph.D candidate, Department  
Microbiology, UMCP. Project: Acquisition  
strains of *Enterococcus* and *Staphylococcus* in

advisor, Dr. Sam

2002 - 2008  
Pathology

Project: Real-time

biological threat toxins.

2003 - 2007  
of Pathology

Project: Effects of

localization and

2004 - 2007  
of Pathology

2005 - 2007

Supervision of Other Students

1993  
Research

and

1994 - 1995  
Research

1995  
Valley, Summer

and ribotype in

1995  
identification of vibrios

1995  
Vertical  
serious risk?

1995 - 1996  
Master of

Studies, Johns Hopkins

for *cps* gene from

1996  
student.

and community-based populations (primary

Joseph)

**Russel Dorsey**, Ph. D. student, Department of

(primary advisor Dr. Niel Constantine)

amplification-boosted detection of

**Damiola Akinmade**, Ph. D. student, Department

(primary advisor Dr. Anne Hamburger)

Epb1 phosphorylation on its subcellular

protein-protein interactions.

**Patricia Anderson**, Ph. D. student, Department

Project: Mutator strains of *Vibrio cholerae*

**Soumya Ganguly**, Graduate Student M.E.S.

(primary advisor Dr. C. Allen Bush)

**Kyanni Buynum**, Gifted Minority Student

Program Project: Detection of Chlamydia

group B *Streptococci* by PCR. (co-advisor)

**Lubna Nabulsi**, Department of Medical and

Technology, Senior Research Project.

Project: Capsules of *Vibrio cholerae*

**Jennifer Kriss**, Undergraduate, Delaware

project. Project: Relationship of serotype

*V. cholerae*

**Aatif Hayat**, High School summer student.

Project: Comparison of methods for

**Carol Swanson**. Pathology Senior Project:

transmission of HIV: is breast feeding a

**William Manyi Nsoesie**, Independent Project,

Science in Interdisciplinary Science

University. Project: Development of probe

*Vibrio cholerae* strain NRT-36S

**Marjorie Paloma**, Undergraduate summer

available methods for

1996-1997

Magnet

Molecular typing of

1997

Research

*aeruginosa*

1997

Research

Project: Testing of

in rabbits.

1997

Research

negative bacteria.

1997

Magnet

Imipenem Resistance

1998

Traineeship.

diarrhea in young

Morris, Jr.)

1998

Research

*V. cholerae* surface

1998

Research

Enterococci:

1998

*Aeromonas*

1998

Talented

Enterococci

Project: Comparison of commercially

identification of *Vibrio* species.

**Luu Pham**, High School student - Woodlawn

Research Mentorship Program Project:

pneumococci.

**Norma Shamoon**, Department of Medical and

Technology, Senior Research Project.

Project: Imipenem Resistance in *Pseudomonas*

**Lisa Nissman**: Department of Medical and

Technology, Senior Research Project.

a *V. cholerae* O139 capsule conjugate vaccine

**Jason Duncan**, Department of Medical and

Technology, Senior Research Project.

Project: Antibiotic resistance in Gram

**Adnan Syed**, High school student - Woodlawn

Research Mentorship Program Project:

in *Pseudomonas aeruginosa*

**Kleanthis Dendrinis**, Medical Student STRTP

Project: does *Aeromonas* cause acute

children. (primary advisor Dr. J. Glenn

**Pranav Suthar**, Department of Medical and

Technology, Senior Research Project.

Project: Immunologic cross-reactivity of

polysaccharides.

**Cyra Ranji**, Department of Medical and

Technology, Senior Research Project.

Project: Antibiotic resistance genes in

Streptomycin and gentamycin

**Kelli Mitz**, undergraduate research project

Project: Detection of virulence genes in

**Rebekah Geil**, Hammond High School Gifted and

Program Independent Research Project

Project: Antibiotic resistance genes in

1999  
of extended-spectrum  
2001  
commercial poultry  
2001  
commercial poultry  
2001  
*E. coli* from  
2002  
center  
2002  
Intern  
resistance genes in  
2002  
(Intern)  
resistance genes in  
2003  
Escherichia coli and  
2003  
antigens  
2003  
Intern  
rods resistant to third  
setting  
2003  
(Intern)  
AmpC resistance

**CharlesK. Cooper**, Infectious Diseases Fellow  
Project: Antibiotic susceptibility testing  
beta-lactamases  
**Mekdes Biru**  
Department of Pathology Summer Intern  
Project: Antibiotic resistant bacteria in  
**Matt Woodford**  
Department of Pathology Summer Intern  
Project: Antibiotic resistant bacteria in  
**Staci McGonigal**  
Summer Intern  
Project: Recovery of quinolone-resistant  
commercial poultry.  
**Matt Woodford**  
Department of Pathology Summer Intern  
Project: Surveillance for ESBL and AmpC  
*E. coli* and *Klebsiella* in a major medical  
**Cori Miller**  
Department of Pathology Minority Summer  
Project: Distribution of ESBL and AmpC  
*E. coli* and *Klebsiella* in a major medical center  
**Jessica Kalwa**  
Villa Julie College Senior Project.  
Project: Distribution of ESBL and AmpC  
*E. coli* and *Klebsiella* in a major medical center  
**Allison Turner**  
Science Fair Project: Interaction between  
Aeromonas from leech and nonleech sources  
**Gregory Solares Brown**  
Department of Pathology Summer Intern  
Project: Genetics of *Vibrio cholerae* O  
**Tamara Huff**  
Department of Pathology Minority Summer  
Project: Distribution of gram-negative  
generation cephalosporins in an ICU  
**Tiffany Langan**  
Villa Julie College Senior Project.  
Project: Horizontal transfer of ESBL and



2004  
(Intern)  
patients  
2005  
(Intern)  
*aeruginosa* in  
2006  
bacilli in the  
2006, 2007  
Project. (Intern)  
2006 - 2007  
physicians white  
2006 - 2007  
Gastrointestinal Colonization  
Bacteria (Primary  
2006 - 2007  
gowns during  
isolation. (Primary mentor

genes in the intensive care setting  
**Rebecca Josowitz**  
Roland Park Country School Senior Project  
Project: Carriage of VRE in hospitalized  
**Katherine Coyle**  
Villa Julie College Senior Project.  
Project: Imipenem resistance in *Pseudomonas*  
the intensive care setting  
**Veronica Edwards**  
BCCC Biotechnology Rotation. (Intern)  
Project: Imipenem resistant Gram-negative  
intensive care setting  
**Diana Miller**  
Villa Julie College Junior & Senior  
**Amy Treacle, MD, Infectious Disease Fellow**  
Project: Carriage of MRSA and VRE on  
coats (Primary mentor Dr A Harris)  
**Kerri Thom, MD, Infectious Disease Fellow**  
Project: Increasing Prevalence of  
with Ceftazidime-Resistant Gram-negative  
mentor Dr A Harris)  
**Graham Snyder, MD, Infectious Disease Fellow**  
Project: Contamination rate of gloves and  
interaction with patients on contact  
Dr A Harris)

Lectures Given within University Courses  
1987  
Microbiology  
1988 - 1990  
Microbiology  
1994  
infections"  
students)  
1996  
the Eighth  
Diagnostic Pathology

"Medical Mycology" MCB440, Pathogenic  
(150 students)  
"Streptococci" MCB440, Pathogenic  
(150 students)  
"Epidemiology of group B Streptococcus  
MEDT 671, Molecular Diagnostics (20  
"Vibrio cholerae O139 Bengal - An Update on  
Pandemic" Seminars in Clinical and  
(20 students)

1995 - 1997 Techniques in	1 day clinical rotation for MEDT433 -
1997 Diseases" PATH608	Biotechnology (8-12 students) "Molecular Diagnostics of Infectious
2000 exercises	Advanced General Pathology. (20 students) Prepared and taught two laboratory
Electrophoresis	- Plasmid Profiles, and Pulsed-field Gel
2001 Electrophoresis	for MEDT470 - Virology and Molecular Diagnostics (23 students) - Plasmid Profiles, and Pulsed-field Gel
2005 Biotechnology	for MEDT470 - Virology and Molecular Diagnostics (20 students) Plague for PATH 789 Special Topics -
2006 Biotechnology	(8 students) Plague for PATH 789 Special Topics -
2008 Biology	(1 student) <i>Vibrio parahaemolyticus</i> and friends for Water PHC 6937 (~15 students)
Laboratory Co-ordinator, UMCP 1983-1990 students)	MCB440, Pathogenic Microbiology (150
Laboratory Instructor, UMCP 1985 - 1989 1984 1983 1982	Immunology (20 students) Biotechnology (15 students) Graduate Virology (15 students) Pathogenic Microbiology (20 students)

CLINICAL ACTIVITIES

1998 - 2007  
Diagnostics,  
System  
1997 - 2003  
Division of Hospital  
1993 - 1998  
Health

Chief, Microbiology and Molecular  
Veterans Affairs Maryland Health Care  
Consultant, Infection Control Program  
Epidemiology, Department of Medicine, UMAB  
Scientific Director, Molecular Diagnostics  
Laboratory, Veterans Affairs Maryland  
Care System, Baltimore.

INVITED PRESENTATIONS

1995  
Contamination of  
Bioscience  
1995.  
1995  
Cholera"  
1995  
1996  
Diseases"  
"Microbiology from  
1996  
Análisis  
Implicaciones en el Programa  
City, Mexico  
1997  
toxoid conjugate  
Biologics Institute,  
1998  
protein  
Carbohydrate  
1998  
1999  
resistant  
sources".  
Risk Assessment.  
Washington, DC

"Death on the Half Shell: *Vibrio vulnificus*  
Seafood" Seminar at Perkin-Elmer, Applied  
Division, Foster City, CA September 15,  
*Vibrio cholerae* O139 Bengal: The Sugar-Coated  
Seminar at FDA, Bethesda, MD, October 12,  
"Molecular Diagnostics for Infectious  
at the 3-M teleconference program  
Maryland in March 1996"  
"Epidemiología Molecular del *Vibrio cholerae*"  
Epidemiológico del Cólera y su  
de Prevención y Control en México, México  
December 10  
*Vibrio cholerae* O139 polysaccharide-tetanus  
vaccine candidate. Massachusetts  
Boston Massachusetts  
*Vibrio cholerae* O139 capsular polysaccharide  
conjugate vaccines. XIth International  
Symposium San Diego, California, August  
"Comparison of quinupristin/dalfopristin-  
*Enterococcus faecium* from clinical and poultry  
Antibiotic Use in Animals: Food Safety and  
A Ceres Forum Georgetown University,

- 1999  
Commercial Poultry  
1999  
clinical and  
pandemic strain"  
Hygiene.
- 2000  
Enterococci in Poultry"  
Regional Veterinary  
2000  
Joint Institute of  
University of Maryland  
September 7, 2000  
2003  
laboratory Science and The  
Medical Center.
- 2004  
testing"  
laboratory Science and The  
Medical Center.
- 2005  
Diarrheal Diseases: or the  
laboratory Science and The  
Medical Center.
- 2008  
Winning?"  
Jacksonville, FL
- May 1999.  
Press Release, 99<sup>th</sup> Annual Meeting of the  
American Society  
of Microbiology, Chicago, Illinois, May  
1999.  
"Transfer of Gentamicin Resistance from  
Strains of Enterococci"  
"The *Vibrio cholerae* O139 Bengal story:  
molecular basis for emergence of a new  
American Society of Tropical Medicine and  
Washington D. C., November 1999  
"The Biology of Antibiotic Resistant  
Grand Rounds, The Maryland Campus of  
Medicine, College Park, MD March 2000  
"Antibiotic Resistance" Fall Colloquium  
Food Safety and Nutrition and the  
Program in Toxicology, Baltimore, MD,  
"ID and treatment of *Vibrio* Infections"  
20<sup>th</sup> Annual Current Topics in Microbiology  
The Maryland Society for Clinical  
Microbiology Laboratory at Anne Arundel  
Annapolis MD February 2003  
"Updates on antibiotic susceptibility  
21<sup>st</sup> Annual Current Topics in Microbiology  
The Maryland Society for Clinical  
Microbiology Laboratory at Anne Arundel  
Annapolis MD February 2004  
"Unexplained Causes of Infectious  
Scoop on Poop"  
22<sup>nd</sup> Annual Current Topics in Microbiology  
The Maryland Society for Clinical  
Microbiology Laboratory at Anne Arundel  
Annapolis MD March 2005  
"Antibiotic Resistance - Are the Superbugs  
Florida Community College at Jacksonville,  
April 2008

PUBLICATIONS

Book Chapters

1. Johnson, J. A. Chapter 58. *Vibrio*. In Murray et al eds Topley and Wilson's Microbiology and Microbial Infections 10<sup>th</sup> Ed. 2006. Edward Arnold Limited; London
2. Abbott, S. L., Janda, J. M., Johnson, J. A., Farmer J. J. III. Chapter 47: *Vibrio* and Related Organisms. In: Manual of Clinical Microbiology, 9<sup>th</sup> ed. Murray et al eds. 2007. ASM Press, Washington DC.

Original Journal Articles/Peer Reviewed Journals

1. Johnson, J. A., Panigrahi, P., and Morris, J. G., Jr. Non-O1 *Vibrio cholerae* NRT36S produces a polysaccharide capsule that determines colony morphology, serum resistance, and virulence in mice. *Infection and Immunity* 1992; 60: 864-9.
2. Wight, A. C., Guo, Y., Johnson, J. A., Nataro, J. P., and Morris, J. G., Jr. Development and testing of a non-radioactive DNA oligonucleotide probe that is specific for *Vibrio cholerae* cholera toxin. *Journal of Clinical Microbiology* 1992; 30: 2302-6
3. Johnson, J. A., Morris, J. G., Jr., and Kaper, J. B. Gene encoding zonula occludens toxin (*zot*) does not occur independently from cholera enterotoxin genes (*ctx*) in *Vibrio cholerae*. *Journal of Clinical Microbiology* 1993; 31: 732-3.
4. Rice, E. W., Johnson, C. H., Clark, R. M., Fox, K. R., Reasoner, D. J., Dunningan, M. E., Panigrahi, P., Johnson, J. A., and Morris, J. G., Jr. *Vibrio cholerae* O1 can assume a 'rugose' survival form that resists killing by chlorine, yet retains virulence. *International Journal of Environmental Health Research* 1993; 3: 89-98.
5. Hayat, U., Reddy, G. P., Bush, C. A., Johnson, J. A., Wight, A. C., and Morris, J. G., Jr. Capsular types of *Vibrio vulnificus*: An analysis of strains from clinical and environmental sources. *The Journal of Infectious Diseases* 1993; 168: 758-62.
6. Johnson, J. A., Salles, C. A., Panigrahi, P., Albert, M. J., Wight, A. C., Johnson, R. J., and Morris, J. G., Jr. *Vibrio cholerae* O139 synonym Bengal is closely related to *Vibrio cholerae* El Tor, but has important differences. *Infection and Immunity* 1994; 62: 2108-10.
7. Comstock, L. E., Maneval, D., Jr., Panigrahi, P., Joseph, A., Levine, M. M., Kaper, J. B., Morris, J. G., Jr., and Johnson, J. A. The capsule and O antigen in *Vibrio cholerae* O139 Bengal are associated with a genetic region not present in *Vibrio cholerae* O1. *Infection and Immunity* 1995; 63: 317-323.
8. Preston, L. M., Xu, Q., Johnson, J. A., Joseph, A., Maneval, D. R., Jr., Husain, K., Reddy, G. P., Bush, C. A., and Morris, J. G., Jr. Preliminary structure determination of the capsular polysaccharide of *Vibrio cholerae* O139 Bengal AI 1837. *Journal of Bacteriology* 1995; 177: 835-8.
9. Morris, J. G., Jr., Losonsky, G. E., Johnson, J. A., Tacket, C. O., Nataro, J. P., Panigrahi, P., and Levine, M. M. Clinical and immunologic

- characteristics of *Vibrio cholerae* O139 Bengal infection in North American volunteers. *The Journal of Infectious Disease* 1995; 171: 903-8.
10. Morris, J. G., Jr., Shay, D. K., Hebden, J. N., McCarter, R. J., Jr., Perdue, B. E., Jarvis, W., Johnson, J. A., Dowling, T. C., Polish, L. B., and Schwalbe, R. S. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center. *Annals of Internal Medicine* 1995; 123: 250-9.
  11. Harrison, L. H., Ali, A., Dwyer, D. M., Libonati, J. P., Reeves, M. W., Elliot, J. A., Billmann, L., Lashkerwala, T., and Johnson, J. A. Relapsing Invasive group B streptococcal infection in adults. *Annals of Internal Medicine* 1995; 123: 421-7.
  12. Comstock, L. E., Johnson, J. A., Mchalski J. M., Morris, J. G., Jr., and Kaper, J. B. Cloning and sequence of a region encoding a surface polysaccharide of *Vibrio cholerae* O139 and characterization of the insertion site in the chromosome of *Vibrio cholerae* O1. *Molecular Microbiology* 1996; 19: 815-26.
  13. Sciortino, C. V., Johnson, J. A. and Hamad, A. Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 *Vibrio cholerae*. *Journal of Clinical Microbiology*. 1996; 34: 897-900.
  14. Wight, A. C., Hill, R. T., Johnson, J. A., Roghman, M-C., Colwell, R. R., and Morris, J. G., Jr. Distribution of *Vibrio vulnificus* in the Chesapeake Bay. *Applied and Environmental Microbiology* 1996; 62: 717-24.
  15. Franco, A. A., Yeh, P.-E., Johnson, J. A., Barry E. M., Guerra, H., Mauer, R., and Morris, J. G., Jr. Cloning and characterization of *dnaE*, encoding the catalytic subunit of replicative DNA polymerase III, from *Vibrio cholerae* strain C6706. *Gene* 1996; 175: 281-283.
  16. Morris, J. G., Jr., Sztein, M. B., Rice, E. W., Nataro, J. P., Losonsky, G. A., Panigrahi, P., Tacket, C. O., and Johnson, J. A. *Vibrio cholerae* O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. *The Journal of Infectious Diseases* 1996; 174: 1364-8.
  17. Schwalbe, R. S., McIntosh, A. C., Qaiyumi, S., Johnson, J. A., Johnson, R. J., Furness, K. M., Holloway, W. J., and Steele-More, L. *In vitro* activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. *Antimicrobial Agents and Chemotherapy* 1996; 40: 2416-9.
  18. Roghmann, M-C., Qaiyumi S., Johnson, J. A., Schwalbe, R., and Morris, J. G., Jr. Recurrent vancomycin-resistant *Enterococcus faecium* bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. *Clinical Infectious Diseases* 1997; 24: 514-5.
  19. Losonsky, G. A., Lim Y., Mtamedi, P., Comstock, L. E., Johnson, J. A., Morris, J. G., Jr., Tacket, C. O., Kaper, J. B., , and Levine, M. M. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine *Vibrio cholerae* O139: specificity and relevance to immunity. *Clinical and Diagnostic Laboratory Immunology*. 1997; 4: 264-9.

20. Bush, C. A., Patel, P., Gunawardena, S., Powell, J., Joseph, A., Johnson, J. A., and Morris, J. G. Classification of *Vibrio vulnificus* strains by the carbohydrate composition of their capsular polysaccharides. *Analytical Biochemistry* 1997; 250: 186-195
21. Franco, A. A., Fix, A. D., Prada, A., Paredes E., Palomino, J. C., Wight, A. C., Johnson, J. A., McCarter, R., Guerra, H., and Morris, J. G., Jr. Cholera in Lima, Peru, correlates with prior isolation of *Vibrio cholerae* from the environment. *American Journal of Epidemiology* 1997; 146: 1067-1075.
22. Karaolis, D. K. R., Johnson, J. A., Bailey, C. C., Boedeker, E. C., Kaper, J. B., and Reeves, P. R. A *Vibrio cholerae* pathogenicity island associated with epidemic and pandemic strains. *Proceedings of the National Academy of Science, USA*. 1998; 95: 3134-9.
23. Karaolis, D. K. R., Somara, S. Maneval, D. R., Johnson, J. A., and Kaper, J. B. A bacteriophage encoding a pathogenicity island, type IV pilus, and receptor for CTXØ in epidemic *Vibrio cholerae*. *Nature* 1999; 399: 375-379.
24. Sohamannan, S., Deng YK, Li, M Sulakvelidze A, Kaper JB, Johnson, J. A. Nair GB and Morris JG, Jr. Cloning and sequencing of the genes downstream of the *wbf* gene cluster of *Vibrio cholerae* serogroup O139 and analysis of the junction genes in other serogroups. *Infection and Immunity* 1999; 67: 5033-40
25. Gunawardena, S., Fiore, C., Johnson, J. A., and Bush, C. A. The conformation of a rigid tetrasaccharide epitope in the capsular polysaccharide of *Vibrio cholerae* O139. *Biochemistry* 1999; 38: 12062-71
26. Ali, A Johnson, J. A. Franco, A. A., Metzger, D. J., Morris, J. G., Jr., Connell, T. D. and Sohamannan, S. Mutations in the extracellular protein secretion (eps) pathway genes interfere with rugose polysaccharide production and motility of *Vibrio cholerae*. *Infection and Immunity* 2000; 68: 1967-74.
27. Ali A, Mahmud ZH, Presswala S, Morris JG Jr., Sohamannan, S, and Johnson JA Sequence analysis of *TnphoA* insertion sites in *Vibrio cholerae* mutants defective in rugose polysaccharide production. *Infection and Immunity* 2000; 68: 6857-6864.
28. Stine O. C., Sohamannan S., Gou Q., Zheng S., Morris J. G., Jr., and Johnson J. A. Phylogeny of *Vibrio cholerae* based on *recA* sequence. *Infection and Immunity* 2000; 68: 7180-7185.
29. Hayes Jr, McIntosh AC, Qaiyumi S, Johnson JA, English LL, Carr LE, Wagner DD, and Joseph SW High frequency recovery of quinupristin (Synercid) resistant *Enterococcus faecium* isolates from the poultry production environment *Journal of Clinical Microbiology* 2001; 39: 2298-2299
30. Henning KJ, Hall EL, Dwyer DM Billmann L, Schuchat A, Johnson JA, Harrison LH, and the Maryland Emerging Infections Program Invasive group B streptococcal disease in Maryland nursing home residents *The Journal of Infectious Diseases* 2001; 183: 1138-42.

31. Siddiqui AH, Mulligan ME, Mahenthiralingam E, Hebden J, Brewink J, Qaiyumi S., Johnson JA and Li Puma JJ. An episodic outbreak of genetically related *Burkholderia cepacia* among non cystic fibrosis patients at a university hospital. *Infection Control and Hospital Epidemiology* 2001; 22: 419-422.
32. Anriany YA, Weiner RM, Johnson JA, De Rezende CE, and Joseph SW. *Salmonella enterica* serovar typhimurium DT104 displays a rugose phenotype. *Applied and Environmental Microbiology* 2001; 67: 4048-4056
33. Harris AD, Perencevich E, Roghmann MC, Morris JG Jr., Kaye K, and Johnson JA. Risk factors for piperacillin tazobactam resistant *Pseudomonas aeruginosa* among hospitalized patients. *Antimicrobial Agents and Chemotherapy* 2002; 46: 854-8.
34. Harris AD, Smith D, Johnson JA, Bradham DD and Roghmann M C. Risk factors for imipenem resistant *Pseudomonas aeruginosa* among hospitalized patients. *Clinical Infectious Diseases* 2002; 34: 340-5
35. Smith DL., Harris AD, Johnson JA, Silbergeld EK, Morris JG Jr. Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. *Proceedings of the National Academy of Science, USA* 2002; 99: 6434-6439
36. Smith-Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, Johnson JA, Goering RV, and Thomson KS. Plasmid-mediated, carbapenem-hydrolyzing  $\beta$ -lactamase, KPC-2, in *Klebsiella pneumoniae* isolates. *Journal of Antimicrobial Chemotherapy* 2003; 51, 711-714.
37. Adeyeye J, Azurmendi HF, Stroop CJM, Sohamman S, Williams AL, Adetumbi AM, Johnson JA, Bush CA. Conformation of the hexasaccharide repeating subunit isolated from the *Vibrio cholerae* O139 capsular polysaccharide. *Biochemistry* 2003; 42: 3979-88
38. Smith DL, Johnson JA, Harris AD, Furuno JP, Perencevich EN, and Morris JG, Jr. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in *Enterococcus faecium*. *The Lancet Infectious Diseases* 2003; 3: 241-9
39. Donabedian SM, Thal LA, Hershberger E, Perri MB, Chow JW, Bartlett P, Jones R, Joyce K, Rossiter S, Gay K, Johnson J, Mackinson C, Debess E, Midden J, Angulo F, Zervos M. Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food. *Journal of Clinical Microbiology*. 2003; 41: 1109-13.
40. Kelly L, Smith DL, Snary EL, Johnson JA, Harris AD, Woldridge M, Morris JG Jr. Animal growth promoters: to ban or not to ban?; A risk assessment approach. *International Journal of Antimicrobial Agents*. 2004; 24: 205-12.
41. Harris, AD, Nemoy, LL, Johnson JA, Martin-Carnahan A, Smith, DL, Standiford, H, Perencevich, EN. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: Implications



- for an Active Surveillance Program Infection Control and Hospital Epidemiology. 2004; 25: 105- 108.
42. Roghmann M, Taylor K, Gupta A, Zhan M, Johnson JA, Cross A, Edelman R and Fattom A. Epidemiology of Capsular and Surface Polysaccharide in *Staphylococcus aureus* infections complicated by bacteraemia. *Journal of Hospital Infections* 2005; 59: 27- 32.
  43. Ali, A., Morris JG, Jr., and Johnson, JA. Sugars inhibit expression of the rugose phenotype of *Vibrio cholerae*. *Journal of Clinical Microbiology* 2005 43: 1426- 1429
  44. Nemy LL, Kotetishvili M, Tigno J, Norris AK, Harris AD, Perencevich EN, Johnson JA, Torpey D, Sulakvelidze S, Morris JG, Jr., Stine OC, Multilocus sequence typing (MLST) vs. pulsed field gel electrophoresis (PFGE) for the characterization of extended spectrum beta lactamase (ESBL) producing *E. coli* isolates. *Journal of Clinical Microbiology* 2005 43: 1776- 1781.
  45. Furuno JP, Perencevich EN, Johnson JA, Wight MD, McGregor JC, Morris Jr., JG, Nemy LL, Roghman M, Standiford HC, Hebden JN, Strauss SM, Harris AD. Patients at risk for vancomycin-resistant *Staphylococcus aureus*: Co-colonization with vancomycin-resistant enterococci and methicillin-resistant *Staphylococcus aureus*. *Emerg Infect Dis.* 2005; 11: 1539- 44
  46. Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Finkelstein J, Smith DL, Strauss SM, Perencevich EN. Identifying high-risk groups for carriage of antibiotic-resistant bacteria. *Archives of Internal Medicine.* 2006; 166: 580- 5.
  47. Roghmann MC, Wallin MT, Gorman PH, Johnson JA. Prevalence and natural history of colonization with fluoroquinolone-resistant gram-negative bacilli in community-dwelling people with spinal cord dysfunction. *Archives of Physical Medicine and Rehabilitation.* 2006; 87: 1305- 9
  48. Nataro JP, Mai V, Johnson J, Blackwelder WC, Heimer R, Tirrell S, Edberg SC, Braden CR, Glenn Morris J Jr, Hirshon JM. Diarrheagenic *Escherichia coli* infection in Baltimore, Maryland, and New Haven, Connecticut. *Clinical Infectious Disease.* 2006; 43: 402- 7.
  49. Stine OC, Johnson JA, Norris AK, Perry K, Tigno J, Qaiumi S, Stine MS, Morris JG, Jr., Widespread distribution of tetracycline resistance genes in a confined animal feeding facility. *International Journal of Antimicrobial Agents.* 2007; 29: 348- 352.
  50. Harris, AD, Kotetishvili M, Shurland S, Johnson JA, Morris JG, Nemy LL, Johnson JK. How important is patient-to-patient transmission in extended spectrum  $\beta$ -lactamase *Escherichia coli* acquisition. *American Journal of Infection Control.* 2007; 35: 97- 101.
  51. Chen Y, Johnson JA, Pusch GD, Morris JG, Jr., Stine OC. The genome of non-O1 *Vibrio cholerae* NRT36S demonstrates the presence of pathogenic mechanisms that are distinct from O1 *Vibrio cholerae*. *Infection and Immunity* 2007; 75: 2645- 7

52. Chen Y, Bystricky P, Adeyeye J, Panigrahi P, Ali A, Johnson JA, Bush CA, Morris JG, Jr. and Stine OC. The capsule biogenesis genes are embedded in the lps region in a non-O1 *Vibrio cholerae* NRT36S. *BMC Microbiology*. 2007, 7: 20.
  53. Roghmann MC, Gorman PH, Wallin MT, Kreisel K, Shurland S and Johnson JA. *Staphylococcus aureus* colonization in community-dwelling people with spinal cord dysfunction. *Archives of Physical Medicine and Rehabilitation* 2007; 88: 979- 83
  54. Chen Y, Stine OC, Morris JG, Johnson JA. Genetic variation of capsule/ LPS biogenesis in two serogroup O31 *Vibrio cholerae* isolates. *FEMS Microbiology Letters* 2007; 273: 133- 9.
  55. Harris, AD, McGregor JC, Johnson, JA, Strauss, SM More AC, Standiford HC, Hebden JN, Morris JG, Jr. Risk factors for ICU admission colonization with extended spectrum  $\beta$ -lactamase producing bacteria. *Emerging Infectious Diseases* 2007; 13: 1144- 9
  56. Thom KA, Johnson JA, Strauss SM Furuno JP, Perencevich EN, Harris AD. Increasing prevalence of gastrointestinal colonization with ceftazidime-resistant gram-negative bacteria among intensive care unit patients. *Infection Control and Hospital Epidemiology*. 2007; 28: 1240- 6.
  57. Green HP, Johnson JA, Furuno JP, Strauss SM Perencevich EN, Lautenbach E, Lee D, Harris AD. Impact of freezing on the future utility of archived surveillance culture specimens *Infection Control and Hospital Epidemiology* 2007; 28: 886- 888.
  58. Johnson JK, Arduino SM Stine OC, Johnson JA, Harris AD. Multilocus Sequencing Typing (MLST) Compared to Pulsed-Field Gel Electrophoresis (PFGE) for Molecular Typing of *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*. 2007; 45: 3707- 3712
  59. Harris AD, Perencevich, EM Johnson JK, Paterson DL, Morris JG, Jr., Strauss, SM Johnson, JA patient-to-patient transmission is important in extended spectrum beta-lactamase-producing *Klebsiella pneumoniae* acquisition. *Clinical Infectious Diseases*. 2007; 45: 1347- 50.
- Perencevich, EM McGregor JC, Shardell M Furuno JP, Harris AD, Johnson, JA. Seasonal Variation of Gram-Negative Pathogens in Hospitalized Patients: Association with Average Monthly Temperature. *Journal of the American Medical Association*. (submitted)

Other Articles, Letters

1. Rice, E. W., Johnson, C. J., Clark, R. M., Fox, K. R., Reasoner, D. J., Dunningan M. E., Panigrahi, P., Johnson, J. A., and Morris, J. G., Jr. Chlorine and survival of "rugose" *Vibrio cholerae* (letter). *Lancet* 1992; 340: 740
2. Harrison, L. H., Dwyer, D. M., and Johnson, J. A. Emergence of serotype V group B streptococcal infection among infants and adults (letter). *Journal of Infectious Disease* 1995; 171: 513
3. Harrison, L. H., Dwyer, D. M., and Johnson, J. A. Response to Relapsing group B streptococcal infection (letter). *Annals of Internal Medicine* 1996; 125: 350
4. Johnson, J. A., Joseph, A., and Morris, J. G., Jr. Capsular polysaccharide-protein conjugate vaccines against *Vibrio cholerae* O139 Bengal. In (R. M. Faure, ed.) Cholera Vaccines. 2<sup>nd</sup> Forum in the *Bulletin de l'Institut Pasteur*. 1995; 93: 285- 290. (symposium proceeding)
5. Schwalbe, R. S., McIntosh, A. C., Qaiyumi, S., Johnson, J. A., and Morris, J. G. Jr. Isolation of vancomycin-resistant enterococci from animal feed in the United States (letter) *The Lancet* 1999; 353: 722.
6. Morris, J. G. Jr., McIntosh, A. C., and Johnson, J. A. Contamination of animal feed by multiresistant enterococci (Authors' reply) *The Lancet* 1999; 354: 163
7. Morris, J. G. Jr., McIntosh, A. C., and Johnson, J. A.: Contamination of animal feed by multiresistant enterococci (Authors' reply). *The Lancet* 1999; 354: 163.
8. Smith, D. L. & J. A. Johnson: Antibiotic use in animals and the emergence of antibiotic resistance in human commensal microbes and zoonotic pathogens. *OIE International Standards on Antimicrobial Resistance*, 2003 (symposium proceeding)
9. Furuno, J. P., Maguire, J. H., Green, H. P., Johnson, J. A., Heimer, R., Braden, C. R. and Hirshon, J. M. Clinical utility of multiple stool ova and parasite examinations in low prevalence patient populations. *Clinical Infectious Diseases* 2006; 43: 795- 6

Abstracts

1. Johnson, J. A., Williams, R., and MacQuillan, A. Effects of branched-chain amino acids on the regulation of leucine biosynthesis in *Vibrio parahaemolyticus*. Abstr # . 89<sup>th</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1989.
2. Johnson, J. A., Russell, R. G., and Morris, J. G., Jr. Correlation of colonial morphology and pathogenicity of non-01 *Vibrio cholerae*. Abstr #B207. 91<sup>st</sup> Annual Meeting of the American Society of Microbiology, Dallas, Texas, May 1991.
3. Johnson, J. A., Panigrahi, P., Russell, R. G., and Morris, J. G., Jr. Role of hemolysin in the pathogenesis of non-serogroup 01 *Vibrio cholerae*. 31<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 1991.
4. Johnson, J. A., Panigrahi, P., and Morris, J. G., Jr. Evaluation of the role of surface polysaccharide and hemolysin in the pathogenesis of non-01 *Vibrio cholerae*. Poster, 27<sup>th</sup> Joint Conference of the U.S.-Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Charlottesville, VA, September 1991.
5. Wight, A. C., Guo, Y.-F., Christy, J. B., Johnson, J. A., Hayat, U., Hill, R. T., and Colwell, R. R. Incidence of *Vibrio vulnificus* in the Chesapeake Bay. Abstr #Q258. 92<sup>nd</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.
6. Panigrahi, P., Srinivas, S., Johnson, J. A., and DeTolla, L. J. Modulation of immunity in non-01 *Vibrio cholerae*. Abstr #B316. 92<sup>nd</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.
7. Johnson, J. A., Joseph, A., Panigrahi, P., and Morris, J. G., Jr. Frequency of encapsulated versus unencapsulated strains of non-01 *Vibrio cholerae* isolated from patients with septicemia or diarrhea, or from environmental sources. Abstr #B277. 92<sup>nd</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1992.
8. Panigrahi, P., Srinivas, S., Johnson, J. A., and Morris, J. G., Jr. Microfilament dependent invasion of Caco-2 cells by Non-01 *Vibrio cholerae*. Abstr #614, 32<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.
9. Johnson, J. A., Salles, C. A., and Morris, J. G., Jr. Correlation of heat-stable enterotoxin and capsule type of non-01 *Vibrio cholerae*. Abstr #613, 32<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 1992.
10. Joseph, A., Zulty, J., Russell, R., Johnson, J. A., and Morris, J. G., Jr. AIN-76A produces fatty liver damage in outbred CD-1 mice. Abstr #B246, 93<sup>rd</sup> Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
11. Lashkerwala, T., Johnson, J. A., Lovchik, J., and Morris, J. G., Jr. Molecular epidemiology of group B streptococci (GBS), and assessment of

- GBS typing by arbitrary primer-PCR (AP-PCR). Abstr #C260, 93<sup>rd</sup> Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
12. Johnson, J. A., Hopkins, R. J., Panigrahi, P., and Morris, J. G., Jr. Evidence that the polysaccharide capsule of non-O1 *Vibrio cholerae* NRT-36S mediates attachment to epithelial cells. Abstr #B320, 93<sup>rd</sup> Annual Meeting of the American Society of Microbiology, Atlanta, GA, May, 1993
  13. Morris, J. G. Jr., Johnson, J. A., Tacket, C., Losonsky, G., Rice, E. W., Sztein, M., and Nataro, J. Rugose survival forms of *Vibrio cholerae* O1 are virulent for humans. 1993 Annual Meeting of the Infectious Diseases Society of America, October, New Orleans, LA, 1993
  14. Johnson, J. A., Albert, M.J., Panigrahi, P., Mchalski, J., Ali, M.A., Johnson, R. J., Kaper, J. B., Morris, J. G., Jr. Characterization of non-O1 *Vibrio cholerae* strains from the Bangladesh Epidemic. Abstr # 33<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, October, New Orleans, LA, 1993
  15. Morris, J. G. Jr., Johnson, J. A., E. W. Rice, Tacket, C. O., G. A. Losonsky, M.B. Sztein, and J. P. Nataro. *Vibrio cholerae* O1 can assume a rugose survival form which resists chlorination, but retains virulence for humans. 29<sup>th</sup> Joint Conference on the U. S. -Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Monterey, California, December 1993.
  16. Johnson, J. A., Albert, M.J., Panigrahi, P., Wight, A. C., Joseph, A., Comstock, L., Trucksis, M., Mchalski, J., Johnson, R. J., Kaper, J. B., Morris, J. G., Jr. Non-O1 *Vibrio cholerae* (O139 synom Bengal) form the India/Bangladesh epidemic are encapsulated. 29<sup>th</sup> Joint Conference on the U. S. -Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Monterey, California, December 1993.
  17. Johnson, J. A., Comstock, L., Johnson, R. J., Kaper, J. B., Morris, J. G., Jr. *toxR* is common in nontoxigenic *Vibrio cholerae*. Abstr #B274, 94<sup>th</sup> Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 23-27, 1994.
  18. Johnson, J. A., Comstock, L., Losonsky, G., Yu, L., Johnson, R. J., Kaper, J. B., Morris, J. G., Jr. Encapsulated *Vibrio cholerae* O139 Bengal are protected from serum killing. Abstr #B273, 94<sup>th</sup> Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 1994.
  19. Panigrahi P., Joseph, A., Johnson, J., Lehrer, R. I., and Morris, J. G., Jr. Effects of defensins on vibrio species. Abstr #B281. 94<sup>th</sup> Annual Meeting of the American Society of Microbiology, Las Vegas, Nevada, May 1994.
  20. Harrison, L. H., Johnson, J. A., Ali, A., Elliot, J. A., Reeves, M.W., Billman, L., Dwyer, D.M., and the Maryland Bacterial Invasive Disease Surveillance Group. 1994. Relapsing group B streptococcal bacteremia among adults. 34<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, October, Orlando Florida, 1994

21. Verma, P. R., Allen, N. E., Hobbs, J. N., Jr., Johnson, J. A., Morris, J. G., Jr., and Schwalbe, R. S.. Characterization of vancomycin resistance in *Staphylococcus haemolyticus*. Abstr #637. 34<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, October, Orlando Florida, 1994
22. Comstock, L. E., J. A. Johnson, and J. B. Kaper. Cloning of a region associated with capsule and O antigen expression of *Vibrio cholerae* serogroup O139. Abstr #B28, 95<sup>th</sup> Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
23. Panigrahi, P., Bamford, P., Joseph, A., G. Losonsky, and Johnson, J. Human immune response to non-O1 *Vibrio cholerae* serotype O139. Abstr #B291, 95<sup>th</sup> Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
24. Johnson, J., Echeverria, P., Cole, E. M., McDowell, C. I., and Hubner, R. J. Recognition of pathogenic strains of *Vibrio cholerae* with restriction fragments containing ribosomal RNA operon sequences. Abstr #R8, 95<sup>th</sup> Annual Meeting of the American Society of Microbiology, May, Washington DC., 1995
25. Johnson, J. A., Li, Z., Qaiyumi S, Harrison, T, Morris, J. G., Jr., Johnson, R. J., and Schwalbe, R. Distribution of genotypes of vancomycin resistant enterococci (VRE) differs in ill versus colonized patients. Abstr #E37, 35<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, October, San Francisco CA, 1995
26. Johnson, J. A., Comstock L. E., Mchalski, J., Yu, J., Kaper, J. B., and Morris, J. G., Jr. Characterization of the *rfb* region of *Vibrio cholerae* O139 Bengal responsible for expression of O antigen and capsule. Poster, 31<sup>st</sup> Joint Conference on the U. S. -Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Kiawah Island, South Carolina, December 1995.
27. Panigrahi, P., Johnson, J. A., Losonsky, G., and Morris, J. G., Jr. Immune Response to *Vibrio cholerae* Serotypes O1 and O139. Poster, 31<sup>st</sup> Joint Conference on the U. S. -Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Kiawah Island, South Carolina, December 1995.
28. Joseph, A., and Johnson, J. A. Parenteral injection of an O139 *Vibrio cholerae* capsular polysaccharide-tetanus toxoid conjugate is protective against diarrhea in the RITARD model. 96<sup>th</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
29. Li, Z., Schwalbe, R. S., Qaiyumi, S., Johnson, R. J., and Johnson, J. A. Detection of vancomycin-resistant enterococci in stool specimens by the polymerase chain reaction. 96<sup>th</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
30. Franco, A. A., Wight, A. C., Prada, A., Paredes E., Palomino, J. C., Johnson, J. A., Guerra, H., and Morris, J. G., Jr. Abstr #Q394. Distribution of toxigenic *Vibrio cholerae* in sewage, river, and irrigation water in Lima Peru. 96<sup>th</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.

31. Xu, D.-Q., Comstock, L. E., Johnson, J. A., and Morris, J. G., Jr. Molecular cloning and localization of the genes essential for expression of *Vibrio cholerae* O139 polysaccharide in *E. coli*. Abstr #E29, 96<sup>th</sup> Annual Meeting of the American Society of Microbiology, New Orleans, LA, May 1996.
32. Carnahan, A., Ali, A., Kriss, J., Daugherty, S., Hayat, A., Johnson, R. J., and Johnson, J. A. Evaluation of three commercial identification systems with clinically significant *Vibrio* species. Abstr #D108, 36<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September, New Orleans, LA, 1996.
33. Ali, A., Franco, A. A., Morris, J. G., Jr., Johnson, R. J., and Johnson, J. A. Abstr #D89. Insertion of *TnphoA* into *espD* prevents expression of the rugose phenotype in *Vibrio cholerae*. 97<sup>th</sup> Annual Meeting of the American Society of Microbiology, Miami Beach, FL, May 1997.
34. Karaolis, D. K. R., Johnson, J. A., Boedeker, E. C., and Reeves, P. R. A large pathogenicity island in epidemic and pandemic *Vibrio cholerae*. Abstr #B330, 97<sup>th</sup> Annual Meeting of the American Society of Microbiology, Miami Beach, FL, May 1997.
35. Johnson, J. A., Cole, E. M., Banks, J. G., Carnahan, A., Johnson, R. J., Bruch, D. L., and Corby M. D. Characterization of clinically important *Vibrio* species by the Riboprinter™ Microbial Characterization System 8<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May, 1997.
36. Sozhamannan, S., Johnson, J. A., and Morris, J. G. Jr. Mechanism of horizontal gene transfer - the *Vibrio cholerae* O139 paradigm. Microbial Pathogenesis and Host Defense, Cold Spring Harbor Laboratory Conference. September, Cold Spring Harbor, New York 1997.
37. Washburn, R. G., Charles, C., Johnson, J., and Morris, J. G. Jr. Binding of complement component C3 to serum-resistant *Vibrio vulnificus* and *Vibrio cholerae* is impaired. Abstr # B46, 37<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September, Toronto, Canada 1997.
38. Roghmann, M., Brewink, J., Hebden, J., Daugherty, S., Johnson, J. A., and Morris, J. G., Jr. Rapid increase in isolation of Imipenem-resistant *Pseudomonas aeruginosa*. Abstr # C27, 37<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September, Toronto, Canada 1997.
39. Blake, R. A. L., Bamford, P. D., O'Brien J., Johnson, J. A., and PaniGRAHI, P. Developmental expression of surfactant protein A in the rat gastrointestinal tract. Eastern Society for Pediatric Research, February, Atlantic City, NJ, 1998.
40. Karaolis, D. K. R., Sozhamannan, S., Johnson, J. A., and Kaper, J. B. Novel non-O1/non-O139 *Vibrio cholerae* containing the VPI and CTXØ. Abstr #B179, 98<sup>th</sup> Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.

41. Fiore, C. R., Gunawardena, S., Johnson, J. A., Trigianni, E., and Bush, C. A. *Vibrio cholerae* O139 capsular polysaccharide conformation. Abstr #B408, 98<sup>th</sup> Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.
42. Trigianni, E., Johnson, J. A., and Powell, J. *Vibrio cholerae* O139 Bengal capsular polysaccharide induces cytokine and chemokine production from human peripheral blood mononuclear cells (PBMCs) in vitro. Abstr #E75, 98<sup>th</sup> Annual Meeting of the American Society of Microbiology, Atlanta, Georgia, May 1998.
43. Johnson, J. A., and Morris, J. G., Jr. *Vibrio cholerae* O139 capsular polysaccharide protein conjugate vaccines. XIX<sup>th</sup> International Carbohydrate Symposium, San Diego, California, August 1998
44. Pfaller, MA, Hollis R, Harrington S, Merz WG, Johnson J, Schwalbe R, Morris JG Jr., Berg D, Steele-More L, Cole EM, Hochberg AM, Perl T, Roghman MC, and Fritschel SJ. Geographical Distribution and antibiotic resistance of clinically-significant *Staphylococcus aureus* ribotypes as determined by an electronically-linked network of automated ribotyping systems. Abstr (late-breaker), 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 1998
45. U. S. - Bangladesh Cholera Working Group (Sack RB, Sack DA, Colwell RR, Huq A, Chun J, Zo Y, Grim C, Morris JG, Johnson JA, Ali A, Longini IM, Nizam A, Siddique AK, Islam MS, Yunus MD, Faruque SM, Qadri F, Albert M) Epidemiology and ecology of *Vibrio cholerae* in Bangladesh. , 34<sup>th</sup> Joint Conference on the U. S. -Japan Cooperative Medical Science Program - Cholera and Related Diarrheal Diseases, Japan, November, 1998.
46. Qaiyumi S., Ranji C.M, Steele-More L., Furness K., Mackinson C., Schwalbe R.S., and Johnson J. A. Isolation and characterization of a novel high-level quinupristin/dalfopristin resistant *Enterococcus faecium*. Abstr #A-68., 99<sup>th</sup> Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
47. McIntosh A. C., Mackinson C. K., Qaiyumi S., Johnson R. J., Morris, J. G., Schwalbe R. S., and Johnson, J. A. Transfer of gentamicin resistance from commercial poultry strains of enterococci. Abstr #A-66, 99<sup>th</sup> Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
48. Ali A., Johnson J. A., Morris, J. G., Jr., and Sozhamannan, S. The type II secretion system is involved in the expression of rugose polysaccharide by *V. cholerae*. Abstr #B/D-373, 99<sup>th</sup> Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
49. Ali A., Sozhamannan, S., Daugherty S., Morris, J. G., Jr., and Johnson J. A. Physiologic factors affecting expression of the rugose phenotype of *Vibrio cholerae*. Abstr #N-91, 99<sup>th</sup> Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
50. Snyder A. R., Johnson J. A., and Williams H. N. Genetic diversity shown by ribotyping of Bdellovibrios isolated from nature Abstr #N-30, 99<sup>th</sup>



- Annual Meeting of the American Society of Microbiology, Chicago, Illinois, May 1999.
51. Siddiqui, A., Hedden J., Qaiyumi S., Johnson J. A., Li Puma J., McMenamin J., Roghmann M, and Milligan M, An episodic outbreak of *Burkholderia cepacia*. 37<sup>th</sup> IDSA Annual Meeting, Philadelphia, PA November 1999
  52. Johnson J. A. Comparison of quinupristin/dalfopristin-resistant *Enterococcus faecium* from clinical and poultry sources. Antibiotic Use in Animals: Food Safety and Risk Assessment.
  53. Johnson J. A., Dick J, Park C, Steele-More L, Paolucci. In vitro susceptibility of vancomycin sensitive *E. faecalis* to imipenem, meropenem, ciprofloxacin, levofloxacin and trovafloxacin. 1<sup>st</sup> International ASM Conference on Enterococci, Banff, Canada, February 2000
  54. Qaiyumi, S. McIntosh A, Mackinson C, and Johnson JA Streptogramin-resistant *Enterococcus faecium* are highly diverse. 1<sup>st</sup> International ASM Conference on Enterococci, Banff, Canada, February 2000
  55. Fiore CR, and Johnson JA Effect of colitose deletion on O139 *V. cholerae* capsule biology. 100<sup>th</sup> Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
  56. Snyder AR, Walker KE, Johnson JA, and Williams HN. Environmental Bdellovibrions exhibit widespread molecular diversity using 16S PCR-RFLP and ribotyping analyses. 100<sup>th</sup> Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
  57. Sozhamannan S, Ali A, Mahmud ZH, Li M Johnson JA, and Morris JG. O-antigen switching in *Vibrio cholerae* by homologous recombination. 100<sup>th</sup> Annual Meeting of the American Society of Microbiology, Los Angeles, CA, May 2000.
  58. Johnson JA, Qaiyumi S, English LL, Hayes JH, White DG, Joseph SW and Wagner DD. Comparison of streptogramin-resistant *Enterococcus faecium* from poultry and humans. 2000 AVMA Annual Convention, Salt Lake City, UT, July 2000
  59. Joshi M Brull R, Sompali N, Qaiyumi S, Johnson JA, Casper P. Clinical outcomes of Cefepime treatment on infections caused by ESBL- and AmpC-producing Enterobacteriaceae. 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000
  60. Mackinson C, Angulo F, Daugherty S, Johnson JA, and the EIP Enterococci Resistance Study Team Isolation of a vancomycin-resistant *Enterococcus faecium* from commercial poultry. 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000
  61. Qaiyumi S, McIntosh AC, Mackinson CK, Bohrer V, and Johnson JA Effect of Virginiamycin on enterococcus colonization in a chicken model. 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 2000

62. Li M, Chen Y, Shimada T, Johnson JA, Morris JG, Stine OC, and Sozhamannan S. Evidence for the emergence of pathogenic non-O1/non-O139 *Vibrio cholerae* by O-antigen switching. Abstr #. 102<sup>nd</sup> General Meeting American Society of Microbiol. (ASM), Orlando, FL. May 2001
63. McIntosh AC, Qaiyumi S, Johnson JA. 2001 Characterization of Md and High-level Gentamycin gene transfer between enterococci from human and animal origin. Abstr # 112. 102<sup>nd</sup> General Meet. American Society of Microbiol. (ASM), Orlando, FL. May 2001
64. Trigiani-Fernandez ER, Sears CL, Trucksis M, Johnson JA, Powell JL, *Vibrio cholerae* O139 Induces IL-8 Secretion From Human Intestinal Epithelial Cells In Vitro Abstr #. 102<sup>nd</sup> General Meet. American Society of Microbiol. (ASM), Orlando, FL. May 2001
65. Angulo F, Bozigar PS, DeBess E, Donabedian SM, Hershberger E, Johnson J, Johnson S, Jones R, Park M, Perri MB, Rossiter S, Zervos M. Quinupristin-dalfopristin resistance in *Enterococcus faecium* isolated from humans, farm animals and retail food. 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
66. Black JA, Hanson ND, Herrera VL, A Hossain A, Johnson J, Lockhart TJ, Molland ES, Thomson KS. *Klebsiella pneumoniae* (KP) Isolates Producing a Carbapenem Hydrolyzing Enzyme (CHE). 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
67. Donabedian SM, Perri MB, Bozigar PS, Hershberger E, Angulo F, Rossiter S, Jones R, DeBess E, Johnson S, Park M, Johnson J, Zervos M. Quinupristin-dalfopristin resistance in *Enterococcus faecium* isolated from humans, farm animals and retail food. 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
68. Harris AD, Perencevich EN, Roghmann MC, Morris JG, Kaye KS, and Johnson JA. Risk factors for piperacillin-tazobactam-resistant *Pseudomonas aeruginosa* among hospitalized patients. Abstract. 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
69. Molland E S, Johnson J, Black JA, Lockhart TJ, Hossain A, Herrera VL, Hanson ND, Thomson KS. *Klebsiella pneumoniae* (KP) Isolates Producing a Carbapenem Hydrolyzing Enzyme (CHE). 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
70. Perri MB, Donabedian SM, Angulo FJ, Jones R, DeBess E, Park M, Johnson S, Johnson J, Zervos M. Common Molecular Mechanism of Gentamicin Resistance among Enterococci Isolated from Animals, Food and Humans. 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001
71. Thal, LA, Hershberger E, Jones R, Joyce K, Hill B, Marano N, Rossiter S, Angulo F, Clark N, Tenover F, Gilbert L, Franko E, Steiner C, Johnson J, DeBess E, Madden J, Zervos M. Molecular Mechanism of gentamicin resistance among enterococci isolated from humans, food animals, meat

- and poultry. 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2001.
72. Hamel KM, Denys GA, Hazen KC, Murray P, Johnson J, Saubolle M. Detection of Vancomycin resistance with the BD Phoenix™ Automated Microbiology System. Abstr #C-118. 103<sup>rd</sup> General Meeting American Society of Microbiol. (ASM), Salt Lake City, UT. May 2002
73. Nemy LL, Harris AH, Carnahan AM, Morris JG, Johnson JA, Stine OC: Multiple genetically distinct ESBL isolates within single persons. National Foundation for Infectious Disease, Washington, DC, June 2002.
74. Aydanian A, Morris JG, Johnson JA, Carnahan A, Stine OC: Recombination in *Vibrio cholerae*. Prokaryotic Development, American Society for Microbiology, Quebec, July 2002.
75. Gupte A, Wu Y, Propst M, Fiore C, Roghmann M, Johnson J, Edelman R, Taylor K, Fattom A. Serotyping of *Staphylococcus aureus* (SA) Bacteremia Isolates and their In Vitro Opsonophagocytic Killing Mediated by Antibodies Specific to Type 5 (T5), Type 8 (T8) and 336 Polysaccharides (PS). 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.
76. Johnson JA, Murray P, Denys GA, Hazen KC, Saubolle M. Multicenter Evaluation of the BD Phoenix™ System for Detection of Oxacillin Resistant *Staphylococcus aureus*. Abstr #C-117. 103<sup>rd</sup> General Meeting American Society of Microbiol. (ASM), Salt Lake City, UT. May 2002
77. Nemy LL, Johnson JA, Stine, OC, Carnahan AM, Morris, JG, Jr., Perencevich EN, Harris AD. Patient-to-Patient Transmission of ESBLs in Tertiary Care ICUs as Detected by Multi Locus Sequence Typing (MLST). Abstr# C2-709. 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.
78. Aydanian A, Johnson JA, Morris JG, Stine OC: The genetic diversity in *Vibrio cholerae* LPS regions, U. S. Japan Cholera Conference, Washington, D. C. 2003
79. Nemy LL, Johnson JA, Carnahan AM, Harris AD, Morris JG, Jr., Stine, OC. Distribution of TEM and SHV genes in ESBLs. Abstr# C2-1884. 42<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 2002.
80. Nemy LL, Kotetishvili M, Perencevich EN, Harris AD, Tigno JD, Johnson JA, Torpey D, Sulakvelidze D, Morris JG Jr., Stine OC. Multilocus Sequence Typing (MLST) vs. Pulsed Field Gel Electrophoresis (PFGE) for the Characterization of Extended Spectrum Beta Lactamase Producing *E. coli* isolates. 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.
81. Stine OC, Perry K, Tigno JD, Johnson JA, Morris JG. Molecular Characterization Of Tetracycline Resistant Bacteria From A Concentrated Animal Feeding Operation (CAFO) 43<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.

82. Perry K, Tigno JD, Johnson JA, Morris JG, Stine OC: Molecular characterization of tetracycline resistant bacteria from a concentrated animal feeding operation (CAFO). American Biosafety Association, Boston, Mass. October, 2003. **Gross Memorial Prize Winner.**
83. Huff T, Johnson J. Ceftazidime resistant Gram-negative rods in ICU and SICU patients. Abstract. 2003 Annual Biomedical Research Conference for Minority Students. San Diego, CA October 2003
84. Aydanian A, Johnson JA, Morris JG, Stine OC: The genetic diversity in *Vibrio cholerae* LPS regions, Genomes Conference, Hixson, England, April 2004.
85. Panigrahi P, Satpathy R, Nanda N, Pradhan L, Mhapatra S, Morris JG Jr, Johnson J, Wight L, Poole K, Parida S and Gewolb I. Reduction of Infant and Neonatal Deaths by Village Level Education and Training and Early Referral to the Hospital in an Indian Community Setting: Society for Pediatric Research Meeting, May 1-5, 2004, San Francisco.
86. Panigrahi P, Satpathy R, Panda P, Pradhan L, Msra P, Jayakar A, Pote M, Shinkre N, Chaudhry R, Gewolb I, Wight L, Poole K, Morris JG Jr., Parida S and Johnson J. Neonatal Sepsis in India: Microbiology of Infection and Role of Bacterial Colonization Society for Pediatric Research Meeting, May 1-5, 2004 in San Francisco.
87. Roghmann M, Cooper Z, Torpey D, Johnson JA. Prevalence of Resistance to Commonly Used Antibiotics among Gram-Negative Bacilli (GNB) in Community Dwelling People with Spinal Cord Injury (SCI). Abstract #C2-1890, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D. C. November 2004.
88. Stine OC, Johnson JA, Keefer-Norris A, Tigno, J, Stine MS, Silbergeld E, Morris, JG. Widespread Distribution of Tetracycline (tet) Resistance Genes in a Concentrated Animal Feeding Operations (CAFO) Abstract #C2-1985, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D. C. November 2004.
89. Nemy LL, Russo KS, Keefer-Norris A, Tigno J, Johnson JA, Perencevich EN, Morris JG, Stine OC, Harris AD. Multilocus Sequence Typing (MLST) versus Pulsed Field Gel Electrophoresis (PFGE) for the Characterization of Extended Spectrum Beta Lactamase (ESBL) Producing *Klebsiella* Isolates. Abstract #C2-1336, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D. C. November 2004.
90. Black JA, Molland ES, Hossain A, Johnson JA, Campbell M, Lockhart TJ, Olson LB, Thomson KS, Hanson ND. *Klebsiella* Isolates that Co-Produce ESBL and Inducible DHA-Like Plasmid-Mediated AmpC  $\beta$ -Lactamases from Baltimore, MD and Tampa, FL. Abstract #C2-1338, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D. C. November 2004.
91. Nemy LL, Tigno J, Keefer-Norris A, Perencevich EN, Johnson JA, Morris JG, Stine OC, Harris AD: Occurrence of multiple species of ESBL in a

- single patient. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill. November 2004.
92. Furuno JP, McGregor JC, Harris AD, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Finkelstein J, Smith DL, Strauss SM and Perencevich EN. Identifying Patients at High Risk for Colonization by Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant Enterococci upon Hospital Admission: Use of a Clinical Prediction Rule. 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April, 2005. Los Angeles, CA (Oral Presentation)
  93. Khoie T, Shurland S, Stine OC, Johnson JA, Jerrard D, Flanagan J and Roghmann M Methicillin-Resistant *Staphylococcus aureus* (MRSA) \* An Emerging Pathogen in the Community. At the 45th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA September 21, 2005
  94. McGregor JC, Furuno JP, Perencevich EN, Johnson JA, Johnson JK, Langenberg P, Venezia RA, Strauss SM Harris AD. Evaluation of Comorbidity Risk-adjustment Measures for Use in Studies of Colonization by Methicillin-resistant *Staphylococcus aureus* and Vancomycin-resistant Enterococci Upon Hospital Admission. 45<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. December 2005, Washington DC.
  95. Panigrahi P, Mohapatra SS, Satpathy RN, Pradhan L, Msra PR, Chaudhry R, Morris JG, Johnson JA, Gewolb IH, Hansen N, Wight L, and Parida SN. Causes and timing of sepsis and neonatal mortality in the Indian community setting
  96. Gorman P, Roghmann M Wallin M Johnson J. Prevalence of resistance to fluoroquinolones in gram-negative bacilli colonizing community dwelling people with spinal cord dysfunction
  97. Chen Y, Bystricky P, Adeyeye J, Panigrahi P, Ali A, Johnson JA, Bush, CA, Morris JG, Stine OC: The capsule region biogenesis genes are embedded in the LPS region in non-O1 *Vibrio cholerae* NRT36S. FASEB, Tucson, Arizona, 2006.
  98. Arduino SM Harris AD, Tang L, Johnson JA, Stine OC. Molecular mechanisms causing imipenem resistance among *P. aeruginosa* isolates from intensive care units (ICU) patients. Annual Conference on Antimicrobial Resistance. June 26-28. 2006. Bethesda, Maryland. abstract S 7.
  99. Nemy LL, Shurland S, Harris AD, Keefer-Norris A, Langan T, Stine OC, Johnson JA Are ESBL producing *E. coli* and *Klebsiella* from active surveillance cultures clonal? 46th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco September 2006.
  100. Perencevich EN, McGregor JC, Furuno JP, Harris AD, Johnson JA. Seasonal Variation in Three Nosocomial Pathogens: *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Staphylococcus aureus*. 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2006, San Francisco, CA.

101. Arduino SM, Stine OC, Tang L, Poole K, Harris AD, Johnson JA. Mechanisms Contributing to Aminoglycoside Resistance among *P. aeruginosa* from ICU Patients. 46th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco September 2006.
102. Treacle A, Thom KA, Furuno JP, , Straus SM, Johnson JA, Harris AD, Perencevich EN. Methicillin-resistant *Staphylococcus aureus* (MRSA) and White Coats of Healthcare Workers. Abstract #391 17th Annual Scientific meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
103. Thom KA, Johnson JA, Straus SM, Furuno JP, Perencevich EN, Harris AD. Increasing Prevalence of Gastrointestinal Colonization with Ceftazidime-resistant Gram-negative Bacteria among Intensive Care Patients. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
104. Harris AD, Green HP, Johnson JA, Strauss SM, Perencevich EN, Launtenbach E, Lee D, Furuno JP. Impact of Freezing on Future Utility of Archived Surveillance Cultures. 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. April 2007. Baltimore, MD.
105. González Fraga S, Pichel M, Binsztein N, Johnson JA, Morris JG, Stine OC. Lateral transfer of serotype encoding genes in O1 *Vibrio cholerae*. 107th General Meeting American Society of Microbiol May 21 - 26, 2007
106. Chaudhry R, Sharma N, Chandel D, Msra P, Shinkre N, Johnson J, Panigrahi P. Multi-Clonal Spread of ESBL-Producing Gram-Negative Bacterial-Strains Causing Neonatal Sepsis in India: Implication for Future Outbreaks. 107th General Meeting American Society of Microbiol May 21 - 26, 2007
107. Snyder GM, Perencevich EN, Furuno JP, Thom KA, Roghmann M, Netzer G, Johnson JA, Strauss SM, Harris AD. Acquisition of Methicillin-Resistant *Staphylococcus aureus* and Vancomycin-Resistant *Enterococcus* by Healthcare Workers on Infection Control Protective Clothing. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2007, Chicago, IL.
108. Furuno JP, Johnson JA, McDermott PF, Tang L, Warren MS, Strauss SM, Perencevich EN, Morris JG Jr., Blythe D, Lee D, Stine OC. Genetic Relatedness of Enterococci from Humans and Retail Meat and Poultry. 47th annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, September 2007
109. Furuno JP, Hebden JN, Standiford HC, Johnson JA, Perencevich EN, Roghmann M, Harris AD. Prevalence of Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Antibiotic-Resistant *Acinetobacter baumannii* at a Long-Term Acute-Care (LTAC) Facility. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. (ICAAC), Chicago, September 2007
110. Yuansha Chen, Antonina Aydanian, Judith A. Johnson, J. Glenn Morris, Jr., O. Colin Stine. Comparative genomic analysis showed different degree of conservation in different *Vibrio* species. *Vibrio* 2007. November 2007. Paris, France



9/1/07 - 10/31/10  
*Pseudomonas aeruginosa*

Emergence of antibiotic resistance in  
in a hospital  
NIH

Principal Investigator: Judith Johnson

3.6 mo

Total direct costs: \$675,000

First year direct costs: \$225,000

Chaudhry R, Sharma N, Chandel DS, Johnson JA, and Panigrahi P. Prevalence and multi-clonal spread of extended-spectrum  $\beta$ -lactams producing Gram-negative bacterial strains causing neonatal sepsis in India: An implication for future outbreaks

Miller RG, Johnson JA, Hirshon JM and Millinson ET. Novel agar combines sensitivity for *Shigella* with high specificity for *Salmonella*. *Emerging Infectious Diseases* (submitted)